<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>HMG CoA reductase inhibitors (statins) for kidney transplant recipients - Palmer, SC - 2014 | Cochrane Library</title> <meta content="HMG CoA reductase inhibitors (statins) for kidney transplant recipients - Palmer, SC - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005019.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="HMG CoA reductase inhibitors (statins) for kidney transplant recipients - Palmer, SC - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005019.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005019.pub4" name="dc.identifier" scheme="DOI"/> <meta content="HMG CoA reductase inhibitors (statins) for kidney transplant recipients" name="citation_title"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Sankar D Navaneethan" name="citation_author"/> <meta content="Glickman Urological and Kidney Institute, Cleveland Clinic" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Vlado Perkovic" name="citation_author"/> <meta content="The George Institute for International Health" name="citation_author_institution"/> <meta content="David W Johnson" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Sagar U Nigwekar" name="citation_author"/> <meta content="Harvard Medical School" name="citation_author_institution"/> <meta content="Jorgen Hegbrant" name="citation_author"/> <meta content="Diaverum Renal Services Group" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="strippoli@negrisud.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD005019.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005019.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005019.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005019.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cardiovascular Diseases [mortality, *prevention &amp; control]; Cholesterol [blood]; Graft Rejection [prevention &amp; control]; Hydroxymethylglutaryl‐CoA Reductase Inhibitors [adverse effects, *therapeutic use]; Hypolipidemic Agents [therapeutic use]; Kidney Transplantation [*mortality]; Myocardial Infarction [prevention &amp; control]; Randomized Controlled Trials as Topic; Triglycerides [blood]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005019.pub4&amp;doi=10.1002/14651858.CD005019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005019\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005019\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005019.pub4",title:"HMG CoA reductase inhibitors (statins) for kidney transplant recipients",firstPublishedDate:"Jan 27, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005019.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005019.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005019.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005019.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005019.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005019.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005019.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005019.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005019.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005019.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3216 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005019.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0085"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/appendices#CD005019-sec-0090"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/table_n/CD005019StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/table_n/CD005019StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">HMG CoA reductase inhibitors (statins) for kidney transplant recipients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0002">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0003">Sankar D Navaneethan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0004">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0005">Vlado Perkovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0006">David W Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0007">Sagar U Nigwekar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0008">Jorgen Hegbrant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information#CD005019-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information/en#CD005019-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005019.pub4">https://doi.org/10.1002/14651858.CD005019.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005019-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005019-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005019-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005019-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005019-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005019-abs-0002">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005019-abs-0001" lang="en"> <section id="CD005019-sec-0001"> <h3 class="title" id="CD005019-sec-0001">Background</h3> <p>People with chronic kidney disease (CKD) have higher risks of cardiovascular disease compared to the general population. Specifically, cardiovascular deaths account most deaths in kidney transplant recipients. Statins are a potentially beneficial intervention for kidney transplant patients given their established benefits in patients at risk of cardiovascular disease in the general population. This is an update of a review first published in 2009. </p> </section> <section id="CD005019-sec-0002"> <h3 class="title" id="CD005019-sec-0002">Objectives</h3> <p>We aimed to evaluate the benefits (reductions in all‐cause and cardiovascular mortality, major cardiovascular events, myocardial infarction and stroke, and progression of CKD to requiring dialysis) and harms (muscle or liver dysfunction, withdrawal, cancer) of statins compared to placebo, no treatment, standard care, or another statin in adults with CKD who have a functioning kidney transplant. </p> </section> <section id="CD005019-sec-0003"> <h3 class="title" id="CD005019-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials Search Co‐ordinator using search terms relevant to this review. </p> </section> <section id="CD005019-sec-0004"> <h3 class="title" id="CD005019-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that compared the effects of statins with placebo, no treatment, standard care, or statins on mortality, cardiovascular events, kidney function and toxicity in kidney transplant recipients. </p> </section> <section id="CD005019-sec-0005"> <h3 class="title" id="CD005019-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes (lipids, glomerular filtration rate (GFR), proteinuria) and relative risk (RR) for dichotomous outcomes (major cardiovascular events, mortality, fatal or non‐fatal myocardial infarction, fatal or non‐fatal stroke, elevated muscle or liver enzymes, withdrawal due to adverse events, cancer, end‐stage kidney disease (ESKD), acute allograft rejection) together with 95% confidence intervals (CI). </p> </section> <section id="CD005019-sec-0006"> <h3 class="title" id="CD005019-sec-0006">Main results</h3> <p>We identified 22 studies (3465 participants); 17 studies (3282 participants) compared statin with placebo or no treatment, and five studies (183 participants) compared two different statin regimens. </p> <p>From data generally derived from a single high‐quality study, it was found that statins may reduce major cardiovascular events (1 study, 2102 participants: RR 0.84, CI 0.66 to 1.06), cardiovascular mortality (4 studies, 2322 participants: RR 0.68, CI 0.45 to 1.01), and fatal or non‐fatal myocardial infarction (1 study, 2102 participants: RR 0.70, CI 0.48 to 1.01); although effect estimates lack precision and include the possibility of no effect. </p> <p>Statins had uncertain effects on all‐cause mortality (6 studies, 2760 participants: RR 1.08, CI 0.63 to 1.83); fatal or non‐fatal stroke (1 study, 2102 participants: RR 1.18, CI 0.85 to 1.63); creatine kinase elevation (3 studies, 2233 participants: RR 0.86, CI 0.39 to 1.89); liver enzyme elevation (4 studies, 608 participants: RR 0.62, CI 0.33 to 1.19); withdrawal due to adverse events (9 studies, 2810 participants: RR 0.89, CI 0.74 to 1.06); and cancer (1 study, 2094 participants: RR 0.94, CI 0.82 to 1.07). </p> <p>Statins significantly reduced serum total cholesterol (12 studies, 3070 participants: MD ‐42.43 mg/dL, CI ‐51.22 to ‐33.65); low‐density lipoprotein cholesterol (11 studies, 3004 participants: MD ‐43.19 mg/dL, CI ‐52.59 to ‐33.78); serum triglycerides (11 studies, 3012 participants: MD ‐27.28 mg/dL, CI ‐34.29 to ‐20.27); and lowered high‐density lipoprotein cholesterol (11 studies, 3005 participants: MD ‐5.69 mg/dL, CI ‐10.35 to ‐1.03). </p> <p>Statins had uncertain effects on kidney function: ESKD (6 studies, 2740 participants: RR 1.14, CI 0.94 to 1.37); proteinuria (2 studies, 136 participants: MD ‐0.04 g/24 h, CI ‐0.17 to 0.25); acute allograft rejection (4 studies, 582 participants: RR 0.88, CI 0.61 to 1.28); and GFR (1 study, 62 participants: MD ‐1.00 mL/min, CI ‐9.96 to 7.96). </p> <p>Due to heterogeneity in comparisons, data directly comparing differing statin regimens could not be meta‐analysed. Evidence for statins in people who have had a kidney transplant were sparse and lower quality due to imprecise effect estimates and provided limited systematic evaluation of treatment harm. </p> </section> <section id="CD005019-sec-0007"> <h3 class="title" id="CD005019-sec-0007">Authors' conclusions</h3> <p>Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005019-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005019-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005019-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005019-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005019-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005019-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005019-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005019-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005019-abs-0004" lang="en"> <h3>HMG CoA reductase inhibitors (statins) for kidney transplant recipients</h3> <p>Kidney transplant patients experience heart disease more often than the general population. Statins have been shown to decrease cholesterol, heart attacks, strokes and deaths for the general population. The aim of this review was to find out whether statins prevent death and complications from heart disease in people who have had a kidney transplant. We included 17 studies in 3282 adults with a functioning kidney transplant which compared statin therapy to a placebo or standard treatment. Based largely on information from a single, large and well‐conducted study, statins may reduce complications from heart disease although information from the available research is imprecise. The effects of statin treatment on death overall, stroke, kidney function and side‐effects are uncertain in people with a kidney transplant. Large additional studies of statin therapy may improve our confidence that statin treatment can safely prevent serious complications from heart disease for people who have a kidney transplant. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005019-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005019-sec-0085"></div> <h3 class="title" id="CD005019-sec-0086">Implications for practice</h3> <section id="CD005019-sec-0086"> <p>Currently, statin therapy may reduce major cardiovascular events and cardiovascular mortality in kidney transplant recipients, although future research is needed to increase our confidence in this finding. Adverse events from treatment are incompletely understood and need to be considered when deciding on statin use in this population. Statin therapy clearly reduces serum cholesterol levels but has uncertain effects on kidney function and risks of acute rejection. Data are particularly sparse for people who have a kidney transplant who have experienced an acute cardiovascular event. Doses used in available studies are relatively low (simvastatin 10 mg equivalent); the benefits and harms of more intensive therapy are less known. </p> </section> <h3 class="title" id="CD005019-sec-0087">Implications for research</h3> <section id="CD005019-sec-0087"> <p>In light of the widespread adoption of statins, additional research is still needed to improve our confidence in the potential benefits and harms of statin therapy in kidney transplant recipients (where data are currently sparse). Additional studies in transplant populations that evaluate cardiovascular and mortality outcomes with more intensive lipid lowering together with systematic ascertainment and reporting of adverse treatment toxicity are required. Randomised data for primary and secondary prevention of cardiovascular disease in the transplant setting would be informative. In addition, post‐marketing surveillance would provide additional important data about treatment harms of statins in this population. Studies that include people with a kidney transplant irrespective of baseline serum total cholesterol would be relevant. Since performing large studies is difficult and costly to individual centres, a trialists’ consortium may assist with infrastructure, recruitment and follow‐up of statin studies in kidney transplant recipients. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005019-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005019-sec-0029"></div> <div class="table" id="CD005019-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Statin versus placebo or no treatment for adults kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population: adults with chronic kidney disease</b> </p> <p><b>Settings: kidney transplant recipients</b> </p> <p><b>Intervention: statin</b> </p> <p><b>Comparison: placebo or no treatment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Statin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> (13 to 21) </p> <p><b>3 fewer</b> (7 fewer to 1 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> </p> <p>(0.66 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2102 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> (12 to 37) </p> <p><b>2 more</b> (8 fewer to 17 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> </p> <p>(0.63 to 1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2760 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (2 to 5) </p> <p><b>2 fewer</b> (3 fewer to 0 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> </p> <p>(0.45 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2322 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Absolute approximate event rates of outcomes/year were derived from previously published observational cohort studies. Absolute numbers of people with a functioning kidney transplant with cardiovascular or mortality events avoided or incurred per 1000 treated were estimated using these assumed risks together with the estimated relative risks (and 95% confidence intervals) (<a href="./references#CD005019-bbs2-0062" title="Australia , New ZealandDialysis , Transplant Registry(ANZDATA) . The 33rd Annual Report 2010. http://www.anzdata.org.au/v1/report_2010.html (accessed 19 December 2013). ">ANZDATA 2010</a>; <a href="./references#CD005019-bbs2-0087" title="LentineKL , BrennanDC , SchnitzlerMA . Incidence and predictors of myocardial infarction after kidney transplantation. Journal of the American Society of Nephrology : JASN2005;16(2):496‐506. [PUBMED: 15615820] ">Lentine 2005</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005019-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005019-sec-0030"></div> <section id="CD005019-sec-0031"> <h3 class="title" id="CD005019-sec-0031">Description of the condition</h3> <p>Kidney transplantation numbers are steadily increasing worldwide and survival rates are improving as a consequence of the adoption of more effective immunosuppressive regimens (<a href="./references#CD005019-bbs2-0100" title="USRDS . USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/2011/pdf/v2_ch04_11.pdf2011. [MEDLINE: 14655174] ">USRDS 2011</a>). Cardiovascular disease still accounts for the majority of deaths in kidney transplant recipients (<a href="./references#CD005019-bbs2-0079" title="JardineAG , GastonRS , FellstromBC , HoldaasH . Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet2011;15:1419‐27. ">Jardine 2011</a>; <a href="./references#CD005019-bbs2-0082" title="KasiskeBL , GuijarroC , MassyZA , WiederkherMR , MaJZ . Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology1996;7(1):158‐65. [MEDLINE: 8808124] ">Kasiske 1996</a>; <a href="./references#CD005019-bbs2-0093" title="National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. American Journal of Kidney Diseases2002;39(2):S1‐S266. [MEDLINE: 11904577] ">NKF 2002</a>; <a href="./references#CD005019-bbs2-0100" title="USRDS . USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/2011/pdf/v2_ch04_11.pdf2011. [MEDLINE: 14655174] ">USRDS 2011</a>). Studies conducted in the general population have demonstrated that dyslipidaemia (including increased total cholesterol, triglycerides and low‐density lipoprotein (LDL) cholesterol; and low, high‐density lipoprotein (HDL) cholesterol levels) is a component of the causal pathway leading to cardiovascular mortality. As a consequence, statins have become broadly adopted as the main treatment for high cholesterol levels in the general population, following the results of major studies which demonstrated their impact on cardiovascular and all‐cause mortality (<a href="./references#CD005019-bbs2-0061" title="ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA2002;288(23):2998‐3007. [MEDLINE: 12479764] ">ALLHAT 2002</a>; <a href="./references#CD005019-bbs2-0077" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR , Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol‐lowering with simvastatin in 5963 people with diabetes: a randomized placebo‐controlled trial. Lancet2003;361(9374):2005‐16. [MEDLINE: 12814710] ">HPS 2003</a>; <a href="./references#CD005019-bbs2-0081" title="RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. ">JUPITER 2008</a>; <a href="./references#CD005019-bbs2-0097" title="SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‐than‐average cholesterol concentrations, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Lipid Lowering Arm (ASCOT‐LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149‐58. [MEDLINE: 12686036] ">Sever 2003</a>; <a href="./references#CD005019-bbs2-0099" title="ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study. New England Journal of Medicine1995;333(20):1301‐7. [MEDLINE: 7566020] ">Shepherd 1995</a>). Recent clinical studies and analyses from earlier larger studies have confirmed the cardioprotective effects of statins in people with chronic kidney disease (CKD) (<a href="./references#CD005019-bbs2-0098" title="BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377:2181‐92. ">SHARP 2011</a>). </p> </section> <section id="CD005019-sec-0032"> <h3 class="title" id="CD005019-sec-0032">How the intervention might work</h3> <p>Statins may modulate the risk of transplant rejection by decreasing inflammation, enhancing endothelial function, inhibiting smooth muscle proliferation, and exerting direct antithrombotic effects. These pleiotropic effects noted in clinical and laboratory studies suggested possible benefits of statins on acute allograft rejection. In kidney transplant recipients, where both systemic factors and immunosuppressive regimens play a role in changing cholesterol metabolism (<a href="./references#CD005019-bbs2-0065" title="ClaessonK , MayerAD , SquiffletJP , GrabenseeB , EiglerFW , BehrendM , et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients. Transplantation Proceedings1998;30(4):1292‐4. [MEDLINE: 9636524] ">Claesson 1998</a>; <a href="./references#CD005019-bbs2-0067" title="CosioFG , PesaventoTE , PelletierRP , HenryM , FergusonRM , KimS , et al. Patient survival after renal transplantation III: the effects of statins. American Journal of Kidney Diseases2002;40(3):638‐43. [MEDLINE: 12200817] ">Cosio 2002</a>; <a href="./references#CD005019-bbs2-0072" title="FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] ">Flechner 2002</a>; <a href="./references#CD005019-bbs2-0076" title="HilbrandsLB , DemackerPN , HoitsmaAJ , StalenhoefAF , KoeneRA . The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Journal of the American Society of Nephrology1995;5(12):2073‐81. [MEDLINE: 7579056] ">Hilbrands 1995</a>, <a href="./references#CD005019-bbs2-0073" title="GrothCG , BackmanL , MoralesJM , CalneR , KreisH , LangP , et al. Sirolimus (rapamycin)‐based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation1999;67(7):1036‐42. [MEDLINE: 10221490] ">Groth 1999</a>; <a href="./references#CD005019-bbs2-0080" title="JohnGT , DakshinamurthyDS , Jeyaseelan , JacobCK . The effect of cyclosporine A on plasma lipids during the first year after transplantation. National Medical Journal of India1999;12(1):14‐7. [MEDLINE: 10326324] ">John 1999</a>; <a href="./references#CD005019-bbs2-0089" title="MassyZA . Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation2001;72(6 Suppl):S13‐5. [MEDLINE: 11585238] ">Massy 2001</a>; <a href="./references#CD005019-bbs2-0090" title="MathisAS , DaveN , KnippGT , FriedmanGS . Drug‐related dyslipidemia after renal transplantation. American Journal of Health‐System Pharmacy2004;61(6):565‐85. [MEDLINE: 15061429] ">Mathis 2004</a>, <a href="./references#CD005019-bbs2-0095" title="RaineAE , CarterR , MannJI , MorrisPJ . Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrology Dialysis Transplantation1988;3(4):458‐63. [MEDLINE: 3140134] ">Raine 1988</a>; <a href="./references#CD005019-bbs2-0096" title="SatterthwaiteR , AswadS , SungaV , ShidbanH , BogaardT , AsaiP , et al. Incidence of new‐onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation1998;65(3):446‐9. [MEDLINE: 9484771] ">Satterthwaite 1998</a>), cohort studies have indicated that increased total cholesterol, LDL cholesterol and triglycerides are independent risk factors for allograft rejection and that statin administration is associated with improved patient survival (<a href="./references#CD005019-bbs2-0059" title="AakhusS , DahlK , WideroeTE . Cardiovascular morbidity and risk factors in renal transplant patients. Nephrology Dialysis Transplantation1999;14(3):648‐54. [MEDLINE: 10193814] ">Aakhus 1999</a>; <a href="./references#CD005019-bbs2-0060" title="AkerS , IvensK , GrabenseeB , HeeringP . Cardiovascular risk factors and diseases after renal transplantation. International Urology &amp; Nephrology1998;30(6):777‐88. [MEDLINE: 10195874] ">Aker 1998</a>; <a href="./references#CD005019-bbs2-0101" title="VathsalaA , WeinbergRB , SchoenbergL , GrevelJ , GoldsteinRA , VanBurenCT , et al. Lipid abnormalities in cyclosporine‐prednisone‐treated renal transplant recipients. Transplantation1989;48(1):37‐43. [MEDLINE: 2665233] ">Vathsala 1989</a>). Additionally, retrospective studies have shown that increased cholesterol and triglycerides are also independent risk factors for allograft rejection in kidney transplant recipients (<a href="./references#CD005019-bbs2-0069" title="DelCastilloD , CruzadoJM , Manel DiazJ . The effects of hyperlipidaemia on graft and patient outcome in renal transplantation. Nephrology Dialysis Transplantation2004;19(Suppl 3):iii67‐71. [MEDLINE: 15192140] ">Del Castillo 2004</a>; <a href="./references#CD005019-bbs2-0078" title="IsoniemiH , NurminenM , Tikkanen , vonWillebrandE , KrogerusL , AhonenJ , et al. Risk factors predicting chronic rejection of renal allografts. Transplantation1994;57(1):68‐72. [MEDLINE: 8291116] ">Isoneimi 1994</a>; <a href="./references#CD005019-bbs2-0088" title="MassyZA , KeaneWF , KasiskeBL . Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet1996;347(8994):102‐3. [MEDLINE: 8538301] ">Massy 1996</a>). </p> </section> <section id="CD005019-sec-0033"> <h3 class="title" id="CD005019-sec-0033">Why it is important to do this review</h3> <p>By extrapolation from the results of these observational data and available randomised controlled trials (RCTs) conducted in the general population, statins have been widely used in kidney transplant recipients. However, there are well recognised discrepancies between the results of observational and study data such that an assessment of the effect of statins on survival in kidney transplant recipients needs to be assessed in available RCTs specifically conducted in this population. Since individual studies of statins in transplant recipients may be underpowered to detect treatment effects on mortality, cardiovascular events and kidney outcomes, we have updated our earlier systematic review and meta‐analysis of all available RCTs (<a href="./references#CD005019-bbs2-0103" title="NavaneethanSD , PerkovicV , JohnsonDW , NigwekarSU , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD005019.pub3] ">Navaneethan 2009c</a>) to February 2012. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005019-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005019-sec-0034"></div> <p>We aimed to evaluate the benefits (reductions in all‐cause and cardiovascular mortality, major cardiovascular events, myocardial infarction and stroke, and progression of CKD to requiring dialysis) and harms (muscle or liver dysfunction, withdrawal, cancer) of statins compared to placebo, no treatment, standard care, or another statin in adults with CKD who have a functioning kidney transplant. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005019-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005019-sec-0035"></div> <section id="CD005019-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005019-sec-0037"> <h4 class="title">Types of studies</h4> <p>RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) that evaluated the benefits and harms of statins in adults with a functioning kidney transplant. The first period of randomised cross‐over studies was included. We excluded studies of fewer than eight weeks' duration as such studies were unlikely to permit detection of mortality or cardiovascular outcomes related to statin therapy (<a href="./references#CD005019-bbs2-0064" title="BrielM , SchwartzGG , ThompsonPL , deLemosJA , BlazingMA , vanEsGA , et al. Effects of early treatment with statins on short‐term clinical outcomes in acute coronary syndromes: a meta‐analysis of randomized controlled trials. JAMA2006;295(17):2046‐56. [MEDLINE: 16670413] ">Briel 2006</a>). </p> </section> <section id="CD005019-sec-0038"> <h4 class="title">Types of participants</h4> <section id="CD005019-sec-0039"> <h5 class="title">Inclusion criteria</h5> <p>Studies or subgroups of studies enrolling adult kidney transplant recipients were included irrespective of presence of cardiovascular disease at baseline. </p> </section> <section id="CD005019-sec-0040"> <h5 class="title">Exclusion criteria</h5> <p>Patients with stages 1‐5 CKD and on dialysis (K‐DOQI stage 5 on dialysis) were excluded as these have been evaluated in separate reviews (<a href="./references#CD005019-bbs2-0092" title="NavaneethanSD , PansiniF , PerkovicV , MannoC , PellegriniF , JohnsonDW , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007784] ">Navaneethan 2009a</a>; <a href="./references#CD005019-bbs2-0094" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , NigwekarSU , et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.CD004289.pub5] ">Palmer 2013</a>). </p> </section> </section> <section id="CD005019-sec-0041"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing statins with placebo, no treatment or standard care, or another statin. We excluded studies where a statin was compared with a second non‐statin regimen including fibrate therapy. </p> </section> <section id="CD005019-sec-0042"> <h4 class="title">Types of outcome measures</h4> <section id="CD005019-sec-0043"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005019-list-0001"> <li> <p>Cardiovascular mortality</p> </li> </ol> </p> </section> <section id="CD005019-sec-0044"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005019-list-0002"> <li> <p>All‐cause mortality</p> </li> <li> <p>Major cardiovascular events</p> </li> <li> <p>Fatal and non‐fatal myocardial infarction</p> </li> <li> <p>Fatal and non‐fatal stroke</p> </li> <li> <p>Adverse events attributable to treatment</p> </li> <li> <p>Elevated creatine kinase</p> </li> <li> <p>Elevated liver enzymes</p> </li> <li> <p>Withdrawal due to adverse events</p> </li> <li> <p>Cancer</p> </li> <li> <p>End of treatment lipid levels</p> <ol id="CD005019-list-0003"> <li> <p>Total cholesterol</p> </li> <li> <p>LDL cholesterol</p> </li> <li> <p>HDL cholesterol</p> </li> <li> <p>Triglycerides</p> </li> </ol> </li> <li> <p>End‐stage kidney disease (ESKD)</p> </li> <li> <p>Acute rejection</p> </li> <li> <p>End of treatment proteinuria</p> </li> <li> <p>End of treatment glomerular filtration rate (GFR)</p> </li> </ol> </p> </section> </section> </section> <section id="CD005019-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005019-sec-0046"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register through contact with the Trials' Search Coordinator (to 29 February 2012) using search terms relevant to this review. </p> <p>The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD005019-list-0004"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD005019-sec-0091">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD005019-sec-0047"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD005019-list-0005"> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies.</p> </li> <li> <p>Reference lists of abstracts from nephrology scientific meetings.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD005019-sec-0048"> <h3 class="title" id="CD005019-sec-0048">Data collection and analysis</h3> <section id="CD005019-sec-0049"> <h4 class="title">Selection of studies</h4> <section id="CD005019-sec-0050"> <h5 class="title">Initial review (2009)</h5> <p>The review (<a href="./references#CD005019-bbs2-0103" title="NavaneethanSD , PerkovicV , JohnsonDW , NigwekarSU , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD005019.pub3] ">Navaneethan 2009c</a>) was initially undertaken by six authors (SDN, SN, VP, DJ, JC, GFMS). The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened independently by three authors (SDN, SN, GFMS) who excluded studies that were not applicable. However, studies and reviews that might have included relevant data or information on studies were retained initially. Two authors (SDN, SN) independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. Disagreements were resolved in consultation with GFMS. </p> </section> <section id="CD005019-sec-0051"> <h5 class="title">Updated review (2013)</h5> <p>The update was performed by two independent authors (SDN, SCP) using methods from earlier versions of the review with support from the remaining authors. The same two authors independently screened abstracts retrieved by electronic searches to identify potentially relevant citations for detailed study in full text format. Studies that might include relevant data or information on studies involving statins were initially retained. Studies published in non‐English journals were translated before assessment for inclusion when a non‐English abstract was provided. Disagreements were resolved in consultation with GFMS. </p> </section> </section> <section id="CD005019-sec-0052"> <h4 class="title">Data extraction and management</h4> <section id="CD005019-sec-0053"> <h5 class="title">Initial review (2009)</h5> <p>Data extraction was carried out by the same authors independently using the standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. When more than one publication of one study existed, the publication with the most complete data was included. Disagreements were resolved in consultation with GFMS. </p> </section> <section id="CD005019-sec-0054"> <h5 class="title">Updated review to (2013)</h5> <p>Authors independently extracted data from the eligible studies using standard data extraction forms. Where more than one publication of one study existed, the publication with the most complete data was included. Disagreements between authors were resolved in consultation with GFMS. </p> </section> </section> <section id="CD005019-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors (SDN, SCP) using the risk of bias assessment tool (<a href="./appendices#CD005019-sec-0092">Appendix 2</a>). </p> <p> <ul id="CD005019-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD005019-list-0007"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD005019-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (major cardiovascular events, mortality, adverse events, ESKD, acute rejection), treatment effects were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (lipid parameters, proteinuria, creatinine clearance), the mean difference (MD) was used. </p> </section> <section id="CD005019-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the authors of the studies was requested by written correspondence and relevant information obtained in this manner was included in the review.  </p> </section> <section id="CD005019-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using the Cochran Q (Chi², N‐1 degrees of freedom) and the I² statistic, with a P of 0.05 used for statistical significance. </p> </section> <section id="CD005019-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess potential bias from small‐study effects, we constructed funnel plots for the log RR in individual studies against the standard error of the RR. We carried out formal statistical assessment of funnel plot asymmetry with the Egger regression test (<a href="./references#CD005019-bbs2-0075" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. [MEDLINE: 16345038] ">Harbord 2006</a>). We conducted analyses using Comprehensive Meta‐Analysis (Version 2, Biostat, Englewood, NJ, 2005). </p> </section> <section id="CD005019-sec-0060"> <h4 class="title">Data synthesis</h4> <p>Data were summarised using the Der Simonian‐Laird random‐effects model, but the fixed‐effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. </p> <p>We summarised the quality of the evidence together with absolute treatment effects for mortality and cardiovascular events based on estimated baseline risks using Grading of Recommendations Assessment Development and Evaluation (GRADE) guidelines (<a href="./references#CD005019-bbs2-0074" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">Guyatt 2008</a>) Absolute numbers of adults with a kidney transplant who had cardiovascular events or adverse events avoided or incurred with statin therapy were estimated using the risk estimate for the outcome (and associated 95% CI) obtained from the corresponding meta‐analysis together with the absolute population risk estimated from previously published observational studies (<a href="./references#CD005019-bbs2-0062" title="Australia , New ZealandDialysis , Transplant Registry(ANZDATA) . The 33rd Annual Report 2010. http://www.anzdata.org.au/v1/report_2010.html (accessed 19 December 2013). ">ANZDATA 2010</a>; <a href="./references#CD005019-bbs2-0087" title="LentineKL , BrennanDC , SchnitzlerMA . Incidence and predictors of myocardial infarction after kidney transplantation. Journal of the American Society of Nephrology : JASN2005;16(2):496‐506. [PUBMED: 15615820] ">Lentine 2005</a>). </p> </section> <section id="CD005019-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted prespecified subgroup analyses to explore potential sources of heterogeneity in modifying estimates of the effects of statins in the studies when significant heterogeneity was present. We planned subgroup analyses according to the following participant, intervention, or study‐related characteristics, when subgroups possessed four or more independent studies (statin type, statin dose (equivalent to simvastatin)), baseline cholesterol (&lt; 230 mg/dL versus ≥ 230 mg/dL), age (&lt; 55 years versus ≥ 55 years), proportion with diabetes (≥ 20% versus &lt; 20%), or adequacy of allocation concealment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005019-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005019-sec-0062"></div> <section id="CD005019-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD005019-sec-0064"> <h4 class="title">Results of the search</h4> <p>Our initial review (<a href="./references#CD005019-bbs2-0103" title="NavaneethanSD , PerkovicV , JohnsonDW , NigwekarSU , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD005019.pub3] ">Navaneethan 2009c</a>) included 16 studies. We reviewed in detail an additional 80 reports that were identified by an updated search conducted in February 2012 (<a href="#CD005019-fig-0001">Figure 1</a>). Six new studies were included in this review update review (<a href="./references#CD005019-bbs2-0005" title="CelikA , UnsalA , MutafI , HabifS , OkE , BayindirO . Which dosage of simvastatin in renal transplant patients?. Nephron2000;84(1):81‐2. [MEDLINE: 10644914] ">Celik 2000a</a>; <a href="./references#CD005019-bbs2-0013" title="RaiolaP , ManzoM , SaggeseA . Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):693A. [CENTRAL: CN‐00447330] ">Raiola 1998</a>; <a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>; <a href="./references#CD005019-bbs2-0022" title="VergoulasG , MiserlisG , GakisD , ImvriosG , PapagiannisA , PapanikolaouV , et al. Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]. Nephrology Dialysis Transplantation1999;14(9):A312. [CENTRAL: CN‐00486302] ">Vergoulas 1999</a>). </p> <div class="figure" id="CD005019-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005019-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005019-sec-0065"> <h4 class="title">Included studies</h4> <p>Overall we have included 22 studies, enrolling 3465 participants in the review update. Seventeen studies (3282 participants) compared statin with placebo (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0002" title="ArnadottirM , ErikssonLO , GermershausenJI , ThysellH . Low‐dose simvastatin is a well‐tolerated and efficacious cholesterol‐lowering agent in ciclosporin‐treated kidney transplant recipients: double‐blind, randomized, placebo‐controlled study in 40 patients. Nephron1994;68(1):57‐62. [MEDLINE: 7991041] ">Arnadottir 1994</a>; <a href="./references#CD005019-bbs2-0003" title="BillM , PaczekL , GaciongZ , GradowskaL , LaoM , WyzgalJ , et al. Low dose lovastatin does not improve kidney allograft function during 6‐month observation [abstract]. Nephrology Dialysis Transplantation1995;10(6):1061. [CENTRAL: CN‐00261145] BillM , PaczekL , WyzgalJ , BaciongZ , GradowskaL , LaoM , JuskowaJ , et al. Six‐month treatment with low‐dose lovastatin does not improve kidney allograft function. Polish Journal of Immunology1995;20(4):417‐9. PaczekL , BillM , WyzgalJ , GaciongZ , GradowskaL , JuskowaJ , et al. The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers. Polskie Archiwum Medycyny Wewnetznej1997;97(2):144‐56. [MEDLINE: 9312763] PaczekL , Bill M. WyzgalJ , GradowskaL , GalazkaZ , GaciongZ . Non‐immune factors in chronic rejection. Is there a role for hypolipemic drugs?. Annals of Transplantation1997;2(2):65‐9. [MEDLINE: 9869855] PaczekL , GradowskaL , BillM , GaciongZ , LaoM , JuskowaJ , et al. Treatment with low‐dose lovastatin does not improve kidney allograft function during 6‐month observation [abstract]. Nephrology1997;3(Suppl 1):S574. [CENTRAL: CN‐00461456] ">Bill 1995</a>; <a href="./references#CD005019-bbs2-0006" title="CofanF , GilabertR , ZambonD , NunezI , RosE , CofanM , et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings2002;34(1):384‐8. [MEDLINE: 11959338] CofanF , ZambonD , LagunaJC , CasalsE , RosE , CofanM , et al. Pravastatin improves low‐density lipoprotein oxidation in renal transplantation. Transplantation Proceedings2002;34(2):389‐91. [MEDLINE: 11959339] ">Cofan 2002</a>; <a href="./references#CD005019-bbs2-0007" title="HausbergM , BarenbrockM , StamF , KoschM , KistersK , HeidenreichS , et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):677A. [CENTRAL: CN‐00445668] HausbergM , BarenbrockM , StamF , KoschM , KistersK , SpiekerC , et al. HMG‐CoA‐reductase inhibitors improve brachial artery flow‐mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation1999;14(9):A282. [CENTRAL: CN‐00484274] HausbergM , KoschM , StamF , HeidenreichS , KistersK , RahnKH , et al. Effect of fluvastatin on endothelium‐dependent brachial artery vasodilation in patients after renal transplantation. Kidney International2001;59(4):1473‐9. [MEDLINE: 11260410] KoschM , BarenbrockM , HausbergM . Sustained beneficial effect of a therapy with the HMG‐Co‐A‐reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren‐und Hochdruckkrankheiten2004;33(10):577‐83. [EMBASE: 2004495206] KoschM , BarenbrockM , SuwelackB , SchaeferRM , RahnKH , HausbergM . Effect of a 3‐year therapy with the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase‐inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases2003;41(5):1088‐96. [MEDLINE: 12722044] ">Hausberg 2001</a>; <a href="./references#CD005019-bbs2-0008" title="KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ . Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]. Transplantation2000;69(8 Suppl):S225. [CENTRAL: CN‐00446023] KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ , BastaniB . The effects of lipid‐lowering agents on acute renal allograft rejection. Transplantation2001;72(2):223‐7. [MEDLINE: 11477342] ">Kasiske 2001</a>; <a href="./references#CD005019-bbs2-0009" title="KatznelsonS , WilkinsonAH , DanovitchGM , WangXM , ChiaD , KobashigawaJA , et al. Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]. Journal of the American Society of Nephrology1994;5(3):1017. [CENTRAL: CN‐00601908] KatznelsonS , WilkinsonAH , DanovitchGM , WangXM , ChiaD , OzawaM , et al. The impact of pravastatin on the incidence of acute rejection after renal transplantation and on cellular immune function [abstract]. 14th Annual Meeting American Society of Transplant Physicians (ASTP);1995 May 10‐14; Chicago (USA). 1995. KatznelsonS , WilkinsonAH , KobashigawaJA , WangXM , ChiaD , OzawaM , et al. The effect of pravastatin on acute rejection after kidney transplantation‐‐a pilot study. Transplantation1996;61(10):1469‐74. [MEDLINE: 8633373] ">Katznelson 1996</a>; <a href="./references#CD005019-bbs2-0010" title="LepreF , RigbyR , HawleyC , SaltissiD , BrownA , WalshZ . A double‐blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clinical Transplantation1999;13(6):520‐5. [MEDLINE: 10617243] ">Lepre 1999</a>; <a href="./references#CD005019-bbs2-0011" title="Martinez HernandezBE , PersaudJW , VargheseZ , MoorheadJF . Low‐dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrology Dialysis Transplantation1993;8(7):637‐41. [MEDLINE: 8396749] Martinez‐HernandezB , PersaudJW , VargheseZ , MoorheadJF . Low dose simvastatin (LS) is safe in hyperlipidemic transplant patients treated with CyA [abstract]. Journal of the American Society of Nephrology1992;3(3):869. [CENTRAL: CN‐00461259] ">Martinez Hernandez 1993</a>; <a href="./references#CD005019-bbs2-0012" title="MelchorJL , GracidaC . Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplantation Proceedings1998;30(5):2054. [MEDLINE: 9723390] ">Melchor 1998</a>; <a href="./references#CD005019-bbs2-0014" title="RendersL , Mayer‐KadnerI , KochC . Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients. Nephrology Dialysis Transplantation2001;16(1):141‐6. [MEDLINE: 11209008] RendersL , Mayer‐KadnerI , KochC , BurkhardtK , VeelkenR , SchmiederR , et al. Cerivastatin and atorvastatin: efficacy, safety and drug‐interaction of the new HMG‐COA reductase inhibitors in renal transplant patients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):694A. [CENTRAL: CN‐00447381] ">Renders 2001</a>; <a href="./references#CD005019-bbs2-0015" title="SahuK , SharmaR , GuptaA . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation2001;15(3):173‐5. [MEDLINE: 11389707] SharmaRK , SahuKM , GuptaA , GulatiS , AgarwalDK , KumarA , et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation1999;14(9):A288. [CENTRAL: CN‐00485837] ">Sahu 2001</a>; <a href="./references#CD005019-bbs2-0016" title="GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00671773] GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind, randomized placebo controlled study [abstract no: 1439]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00615908] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416585] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind randomized placebo controlled study [abstract no:3367]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416586] SantosAF , KeitelE , BittarAE , NeumannJ . Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double‐blind, randomized, placebo‐controlled study [abstract no: PO601]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00465849] SantosAF , KeitelE , BittarAE , NeumannJ , FonsecaN , SporlederH , et al. Simvastatin effect on NK cells activity in vivo: a double‐blind randomized, placebo‐controlled study. Transplantation Proceedings2002;34(7):2874‐5. [MEDLINE: 12431639] SantosAF , KeitelE , BittarAE , NeumannJ , FuchsFD , GoldaniJC , et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double‐blind, randomized, placebo‐controlled study. Transplantation Proceedings2001;33(1‐2):1194‐5. [MEDLINE: 11267254] ">Santos 2001</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>; <a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>) and five studies (183 participants) compared two different statin regimens (<a href="./references#CD005019-bbs2-0004" title="CastelaoAM , GrinoJM , AndresE , GilvernetS , SeronD , CastineirasMJ , et al. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplantation Proceedings1993;25(1 Pt 2):1043‐6. [MEDLINE: 8442035] Martinez‐CastelaoA , GrinyoJM , Gil‐VernetS , SeronD , CastineirasMJ , RamosR , et al. Lipid‐lowering long‐term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplantation Proceedings2002;34(1):398‐400. [MEDLINE: 11959343] ">Castelao 1993</a>; <a href="./references#CD005019-bbs2-0005" title="CelikA , UnsalA , MutafI , HabifS , OkE , BayindirO . Which dosage of simvastatin in renal transplant patients?. Nephron2000;84(1):81‐2. [MEDLINE: 10644914] ">Celik 2000a</a>; <a href="./references#CD005019-bbs2-0013" title="RaiolaP , ManzoM , SaggeseA . Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):693A. [CENTRAL: CN‐00447330] ">Raiola 1998</a>; <a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>; <a href="./references#CD005019-bbs2-0022" title="VergoulasG , MiserlisG , GakisD , ImvriosG , PapagiannisA , PapanikolaouV , et al. Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]. Nephrology Dialysis Transplantation1999;14(9):A312. [CENTRAL: CN‐00486302] ">Vergoulas 1999</a>). Notably, the <a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a> study was a large and well‐conducted double‐blinded RCT conducted in transplant patients and most data for the meta‐analyses are derived from this study. </p> <p>Four studies were randomised cross‐over studies (<a href="./references#CD005019-bbs2-0005" title="CelikA , UnsalA , MutafI , HabifS , OkE , BayindirO . Which dosage of simvastatin in renal transplant patients?. Nephron2000;84(1):81‐2. [MEDLINE: 10644914] ">Celik 2000a</a>; <a href="./references#CD005019-bbs2-0011" title="Martinez HernandezBE , PersaudJW , VargheseZ , MoorheadJF . Low‐dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrology Dialysis Transplantation1993;8(7):637‐41. [MEDLINE: 8396749] Martinez‐HernandezB , PersaudJW , VargheseZ , MoorheadJF . Low dose simvastatin (LS) is safe in hyperlipidemic transplant patients treated with CyA [abstract]. Journal of the American Society of Nephrology1992;3(3):869. [CENTRAL: CN‐00461259] ">Martinez Hernandez 1993</a>; <a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>; <a href="./references#CD005019-bbs2-0022" title="VergoulasG , MiserlisG , GakisD , ImvriosG , PapagiannisA , PapanikolaouV , et al. Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]. Nephrology Dialysis Transplantation1999;14(9):A312. [CENTRAL: CN‐00486302] ">Vergoulas 1999</a>). </p> <section id="CD005019-sec-0066"> <h5 class="title">Statin versus placebo or no treatment</h5> <p>Studies varied in sample size (median 48 participants; range 20 to 2102) and were generally small (all but one study (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>) had fewer than 1000 participants). The median statin dose (equivalent to simvastatin) was 10 mg (range 5 to 40 mg). </p> <p>Statin interventions included atorvastatin or cerivastatin (<a href="./references#CD005019-bbs2-0014" title="RendersL , Mayer‐KadnerI , KochC . Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients. Nephrology Dialysis Transplantation2001;16(1):141‐6. [MEDLINE: 11209008] RendersL , Mayer‐KadnerI , KochC , BurkhardtK , VeelkenR , SchmiederR , et al. Cerivastatin and atorvastatin: efficacy, safety and drug‐interaction of the new HMG‐COA reductase inhibitors in renal transplant patients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):694A. [CENTRAL: CN‐00447381] ">Renders 2001</a>); fluvastatin (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0007" title="HausbergM , BarenbrockM , StamF , KoschM , KistersK , HeidenreichS , et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):677A. [CENTRAL: CN‐00445668] HausbergM , BarenbrockM , StamF , KoschM , KistersK , SpiekerC , et al. HMG‐CoA‐reductase inhibitors improve brachial artery flow‐mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation1999;14(9):A282. [CENTRAL: CN‐00484274] HausbergM , KoschM , StamF , HeidenreichS , KistersK , RahnKH , et al. Effect of fluvastatin on endothelium‐dependent brachial artery vasodilation in patients after renal transplantation. Kidney International2001;59(4):1473‐9. [MEDLINE: 11260410] KoschM , BarenbrockM , HausbergM . Sustained beneficial effect of a therapy with the HMG‐Co‐A‐reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren‐und Hochdruckkrankheiten2004;33(10):577‐83. [EMBASE: 2004495206] KoschM , BarenbrockM , SuwelackB , SchaeferRM , RahnKH , HausbergM . Effect of a 3‐year therapy with the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase‐inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases2003;41(5):1088‐96. [MEDLINE: 12722044] ">Hausberg 2001</a>; <a href="./references#CD005019-bbs2-0012" title="MelchorJL , GracidaC . Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplantation Proceedings1998;30(5):2054. [MEDLINE: 9723390] ">Melchor 1998</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>); lovastatin (<a href="./references#CD005019-bbs2-0003" title="BillM , PaczekL , GaciongZ , GradowskaL , LaoM , WyzgalJ , et al. Low dose lovastatin does not improve kidney allograft function during 6‐month observation [abstract]. Nephrology Dialysis Transplantation1995;10(6):1061. [CENTRAL: CN‐00261145] BillM , PaczekL , WyzgalJ , BaciongZ , GradowskaL , LaoM , JuskowaJ , et al. Six‐month treatment with low‐dose lovastatin does not improve kidney allograft function. Polish Journal of Immunology1995;20(4):417‐9. PaczekL , BillM , WyzgalJ , GaciongZ , GradowskaL , JuskowaJ , et al. The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers. Polskie Archiwum Medycyny Wewnetznej1997;97(2):144‐56. [MEDLINE: 9312763] PaczekL , Bill M. WyzgalJ , GradowskaL , GalazkaZ , GaciongZ . Non‐immune factors in chronic rejection. Is there a role for hypolipemic drugs?. Annals of Transplantation1997;2(2):65‐9. [MEDLINE: 9869855] PaczekL , GradowskaL , BillM , GaciongZ , LaoM , JuskowaJ , et al. Treatment with low‐dose lovastatin does not improve kidney allograft function during 6‐month observation [abstract]. Nephrology1997;3(Suppl 1):S574. [CENTRAL: CN‐00461456] ">Bill 1995</a>; <a href="./references#CD005019-bbs2-0015" title="SahuK , SharmaR , GuptaA . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation2001;15(3):173‐5. [MEDLINE: 11389707] SharmaRK , SahuKM , GuptaA , GulatiS , AgarwalDK , KumarA , et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation1999;14(9):A288. [CENTRAL: CN‐00485837] ">Sahu 2001</a>); pravastatin (<a href="./references#CD005019-bbs2-0006" title="CofanF , GilabertR , ZambonD , NunezI , RosE , CofanM , et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings2002;34(1):384‐8. [MEDLINE: 11959338] CofanF , ZambonD , LagunaJC , CasalsE , RosE , CofanM , et al. Pravastatin improves low‐density lipoprotein oxidation in renal transplantation. Transplantation Proceedings2002;34(2):389‐91. [MEDLINE: 11959339] ">Cofan 2002</a>; <a href="./references#CD005019-bbs2-0009" title="KatznelsonS , WilkinsonAH , DanovitchGM , WangXM , ChiaD , KobashigawaJA , et al. Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]. Journal of the American Society of Nephrology1994;5(3):1017. [CENTRAL: CN‐00601908] KatznelsonS , WilkinsonAH , DanovitchGM , WangXM , ChiaD , OzawaM , et al. The impact of pravastatin on the incidence of acute rejection after renal transplantation and on cellular immune function [abstract]. 14th Annual Meeting American Society of Transplant Physicians (ASTP);1995 May 10‐14; Chicago (USA). 1995. KatznelsonS , WilkinsonAH , KobashigawaJA , WangXM , ChiaD , OzawaM , et al. The effect of pravastatin on acute rejection after kidney transplantation‐‐a pilot study. Transplantation1996;61(10):1469‐74. [MEDLINE: 8633373] ">Katznelson 1996</a>); rosuvastatin (<a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>); or simvastatin (<a href="./references#CD005019-bbs2-0002" title="ArnadottirM , ErikssonLO , GermershausenJI , ThysellH . Low‐dose simvastatin is a well‐tolerated and efficacious cholesterol‐lowering agent in ciclosporin‐treated kidney transplant recipients: double‐blind, randomized, placebo‐controlled study in 40 patients. Nephron1994;68(1):57‐62. [MEDLINE: 7991041] ">Arnadottir 1994</a>; <a href="./references#CD005019-bbs2-0008" title="KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ . Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]. Transplantation2000;69(8 Suppl):S225. [CENTRAL: CN‐00446023] KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ , BastaniB . The effects of lipid‐lowering agents on acute renal allograft rejection. Transplantation2001;72(2):223‐7. [MEDLINE: 11477342] ">Kasiske 2001</a>; <a href="./references#CD005019-bbs2-0010" title="LepreF , RigbyR , HawleyC , SaltissiD , BrownA , WalshZ . A double‐blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clinical Transplantation1999;13(6):520‐5. [MEDLINE: 10617243] ">Lepre 1999</a>; <a href="./references#CD005019-bbs2-0011" title="Martinez HernandezBE , PersaudJW , VargheseZ , MoorheadJF . Low‐dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrology Dialysis Transplantation1993;8(7):637‐41. [MEDLINE: 8396749] Martinez‐HernandezB , PersaudJW , VargheseZ , MoorheadJF . Low dose simvastatin (LS) is safe in hyperlipidemic transplant patients treated with CyA [abstract]. Journal of the American Society of Nephrology1992;3(3):869. [CENTRAL: CN‐00461259] ">Martinez Hernandez 1993</a>; <a href="./references#CD005019-bbs2-0016" title="GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00671773] GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind, randomized placebo controlled study [abstract no: 1439]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00615908] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416585] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind randomized placebo controlled study [abstract no:3367]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416586] SantosAF , KeitelE , BittarAE , NeumannJ . Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double‐blind, randomized, placebo‐controlled study [abstract no: PO601]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00465849] SantosAF , KeitelE , BittarAE , NeumannJ , FonsecaN , SporlederH , et al. Simvastatin effect on NK cells activity in vivo: a double‐blind randomized, placebo‐controlled study. Transplantation Proceedings2002;34(7):2874‐5. [MEDLINE: 12431639] SantosAF , KeitelE , BittarAE , NeumannJ , FuchsFD , GoldaniJC , et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double‐blind, randomized, placebo‐controlled study. Transplantation Proceedings2001;33(1‐2):1194‐5. [MEDLINE: 11267254] ">Santos 2001</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>). Median follow‐up duration was four months (range 2 to 61 months); four studies had follow‐up of 12 months or more (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0006" title="CofanF , GilabertR , ZambonD , NunezI , RosE , CofanM , et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings2002;34(1):384‐8. [MEDLINE: 11959338] CofanF , ZambonD , LagunaJC , CasalsE , RosE , CofanM , et al. Pravastatin improves low‐density lipoprotein oxidation in renal transplantation. Transplantation Proceedings2002;34(2):389‐91. [MEDLINE: 11959339] ">Cofan 2002</a>; <a href="./references#CD005019-bbs2-0007" title="HausbergM , BarenbrockM , StamF , KoschM , KistersK , HeidenreichS , et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):677A. [CENTRAL: CN‐00445668] HausbergM , BarenbrockM , StamF , KoschM , KistersK , SpiekerC , et al. HMG‐CoA‐reductase inhibitors improve brachial artery flow‐mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation1999;14(9):A282. [CENTRAL: CN‐00484274] HausbergM , KoschM , StamF , HeidenreichS , KistersK , RahnKH , et al. Effect of fluvastatin on endothelium‐dependent brachial artery vasodilation in patients after renal transplantation. Kidney International2001;59(4):1473‐9. [MEDLINE: 11260410] KoschM , BarenbrockM , HausbergM . Sustained beneficial effect of a therapy with the HMG‐Co‐A‐reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren‐und Hochdruckkrankheiten2004;33(10):577‐83. [EMBASE: 2004495206] KoschM , BarenbrockM , SuwelackB , SchaeferRM , RahnKH , HausbergM . Effect of a 3‐year therapy with the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase‐inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases2003;41(5):1088‐96. [MEDLINE: 12722044] ">Hausberg 2001</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>). Two studies included participants who had no histories of cardiovascular disease (<a href="./references#CD005019-bbs2-0006" title="CofanF , GilabertR , ZambonD , NunezI , RosE , CofanM , et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings2002;34(1):384‐8. [MEDLINE: 11959338] CofanF , ZambonD , LagunaJC , CasalsE , RosE , CofanM , et al. Pravastatin improves low‐density lipoprotein oxidation in renal transplantation. Transplantation Proceedings2002;34(2):389‐91. [MEDLINE: 11959339] ">Cofan 2002</a>; <a href="./references#CD005019-bbs2-0007" title="HausbergM , BarenbrockM , StamF , KoschM , KistersK , HeidenreichS , et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):677A. [CENTRAL: CN‐00445668] HausbergM , BarenbrockM , StamF , KoschM , KistersK , SpiekerC , et al. HMG‐CoA‐reductase inhibitors improve brachial artery flow‐mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation1999;14(9):A282. [CENTRAL: CN‐00484274] HausbergM , KoschM , StamF , HeidenreichS , KistersK , RahnKH , et al. Effect of fluvastatin on endothelium‐dependent brachial artery vasodilation in patients after renal transplantation. Kidney International2001;59(4):1473‐9. [MEDLINE: 11260410] KoschM , BarenbrockM , HausbergM . Sustained beneficial effect of a therapy with the HMG‐Co‐A‐reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren‐und Hochdruckkrankheiten2004;33(10):577‐83. [EMBASE: 2004495206] KoschM , BarenbrockM , SuwelackB , SchaeferRM , RahnKH , HausbergM . Effect of a 3‐year therapy with the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase‐inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases2003;41(5):1088‐96. [MEDLINE: 12722044] ">Hausberg 2001</a>). Median baseline serum LDL cholesterol was 257 mg/dL (range 159 to 319 mg/dL). No study was a post‐hoc subgroup analysis of a larger study in a broader population. Four studies (<a href="./references#CD005019-bbs2-0006" title="CofanF , GilabertR , ZambonD , NunezI , RosE , CofanM , et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings2002;34(1):384‐8. [MEDLINE: 11959338] CofanF , ZambonD , LagunaJC , CasalsE , RosE , CofanM , et al. Pravastatin improves low‐density lipoprotein oxidation in renal transplantation. Transplantation Proceedings2002;34(2):389‐91. [MEDLINE: 11959339] ">Cofan 2002</a>; <a href="./references#CD005019-bbs2-0007" title="HausbergM , BarenbrockM , StamF , KoschM , KistersK , HeidenreichS , et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):677A. [CENTRAL: CN‐00445668] HausbergM , BarenbrockM , StamF , KoschM , KistersK , SpiekerC , et al. HMG‐CoA‐reductase inhibitors improve brachial artery flow‐mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation1999;14(9):A282. [CENTRAL: CN‐00484274] HausbergM , KoschM , StamF , HeidenreichS , KistersK , RahnKH , et al. Effect of fluvastatin on endothelium‐dependent brachial artery vasodilation in patients after renal transplantation. Kidney International2001;59(4):1473‐9. [MEDLINE: 11260410] KoschM , BarenbrockM , HausbergM . Sustained beneficial effect of a therapy with the HMG‐Co‐A‐reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren‐und Hochdruckkrankheiten2004;33(10):577‐83. [EMBASE: 2004495206] KoschM , BarenbrockM , SuwelackB , SchaeferRM , RahnKH , HausbergM . Effect of a 3‐year therapy with the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase‐inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases2003;41(5):1088‐96. [MEDLINE: 12722044] ">Hausberg 2001</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>) excluded people with diabetes. </p> </section> <section id="CD005019-sec-0067"> <h5 class="title">Statin versus another statin</h5> <p>Five studies compared two different statin regimens. Four studies compared two different statins: lovastatin versus simvastatin (<a href="./references#CD005019-bbs2-0004" title="CastelaoAM , GrinoJM , AndresE , GilvernetS , SeronD , CastineirasMJ , et al. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplantation Proceedings1993;25(1 Pt 2):1043‐6. [MEDLINE: 8442035] Martinez‐CastelaoA , GrinyoJM , Gil‐VernetS , SeronD , CastineirasMJ , RamosR , et al. Lipid‐lowering long‐term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplantation Proceedings2002;34(1):398‐400. [MEDLINE: 11959343] ">Castelao 1993</a>); atorvastatin versus fluvastatin <a href="./references#CD005019-bbs2-0013" title="RaiolaP , ManzoM , SaggeseA . Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):693A. [CENTRAL: CN‐00447330] ">Raiola 1998</a>); simvastatin versus pravastatin (<a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>); and lovastatin versus fluvastatin (<a href="./references#CD005019-bbs2-0022" title="VergoulasG , MiserlisG , GakisD , ImvriosG , PapagiannisA , PapanikolaouV , et al. Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]. Nephrology Dialysis Transplantation1999;14(9):A312. [CENTRAL: CN‐00486302] ">Vergoulas 1999</a>); and one compared a lower and higher dose of simvastatin (<a href="./references#CD005019-bbs2-0005" title="CelikA , UnsalA , MutafI , HabifS , OkE , BayindirO . Which dosage of simvastatin in renal transplant patients?. Nephron2000;84(1):81‐2. [MEDLINE: 10644914] ">Celik 2000a</a>). Median duration was 12 months (range 2 to 12 months). All studies had a small sample size (median 32 participants; range 20 to 51). Insufficient data were available to conduct meta‐analyses. </p> </section> </section> <section id="CD005019-sec-0068"> <h4 class="title">Excluded studies</h4> <p>We excluded 35 studies: 10 did not evaluate an appropriate intervention (<a href="./references#CD005019-bbs2-0023" title="BagdadeJD , ShantharamVV , SollekM , AlbersJJ . Effects of clofibrate on plasma lipids and high‐density lipoprotein levels in renal allograft recipients. Clinical Nephrology1979;12(2):83‐6. [MEDLINE: 230927] ">Bagdade 1979</a>; <a href="./references#CD005019-bbs2-0025" title="BlumCB , Rapamune US Study Group. Cholesterol and triglyceride levels in sirolimus‐treated renal transplant recipients [abstract no: A3577]. Journal of the American Society of Nephrology2000;11(Sept):680A. [CENTRAL: CN‐00550429] ">Blum 2000</a>; <a href="./references#CD005019-bbs2-0029" title="CurtisJJ , GallaJH , WoodfordSY , LucasBA , LukeRG . Effect of alternate‐day prednisone on plasma lipids in renal transplant recipients. Kidney International1982;22(1):42‐7. [MEDLINE: 6750206] ">Curtis 1982</a>; <a href="./references#CD005019-bbs2-0032" title="HilbrandsLB , DemackerPN , HoitsmaAJ . Cyclosporin and serum lipids in renal transplant recipients. Lancet1993;341(8847):765‐6. [MEDLINE: 8095674] HilbrandsLB , DemackerPN , HoitsmaAJ , StalenhoefAF , KoeneRA . The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Journal of the American Society of Nephrology1995;5(12):2073‐81. [MEDLINE: 7579056] ">Hilbrands 1993</a>; <a href="./references#CD005019-bbs2-0033" title="IchimaruN , TakaharaS , KokadoY , WangJD , HatoriM , KameokaH , et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis2001;158(2):417‐23. [MEDLINE: 11583721] ">Ichimaru 2001</a>; <a href="./references#CD005019-bbs2-0034" title="ImamuraR , IchimaruN , MoriyamaT , ShiY , NambaY , NonomuraN , et al. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus. Clinical Transplantation2005;19(5):616‐21. [MEDLINE: 16146552] ">Imamura 2005</a>; <a href="./references#CD005019-bbs2-0035" title="CampistolJM , LegendreC , CastegnetoM , HartmannA , European US Global and Tri‐Continental Study Groups. The effect of sirolimus on lipids on renal transplant recipients: results from clinical trials [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):880A. [CENTRAL: CN‐00550752] ">Kahan‐301 2000</a>; <a href="./references#CD005019-bbs2-0042" title="KaisarM , ArmstrongK , PrinsJ , MarwickT , JohnsonD , HawleyC , et al. The impact of aggressive cardiovascular risk modification on carotid intima media thickness and brachial artery reactivity in renal transplant recipients [abstract no: 132]. Nephrology2008;13(Suppl 3):A134. [CENTRAL: CN‐00766731] KaisarMO , ArmstrongK , HawleyC , CampbellS , MudgeD , JohnsonDW , et al. Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrology2009;10:29. [MEDLINE: 19821969] ">LANDMARK 2 2009</a>; <a href="./references#CD005019-bbs2-0047" title="OkE , KursatS , AlevM , TobuM , TokatY , AkcicekF , et al. Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients. Nephron1996;73(3):491‐2. [MEDLINE: 8832618] ">Ok 1996</a>; <a href="./references#CD005019-bbs2-0057" title="WissingKM , UngerP , GhisdalL , BroedersN , BerkenboomG , CarpentierY , et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation2006;82(6):771‐8. [MEDLINE: 17006324] ">Wissing 2006</a>); 10 compared a statin with an active non‐statin intervention (<a href="./references#CD005019-bbs2-0024" title="Blechman‐KromI . An interventional trial in established chronic renal allograft rejection. www.clinicaltrials.gov/ct2/show/NCT00005010 (accessed 19 December 2013). ">Blechman‐Krom 2000</a>; <a href="./references#CD005019-bbs2-0027" title="CastroR , QueirosJ , FonsecaI , PimentelJP , HenriquesAC , SarmentoAM , et al. Therapy of post‐renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrology Dialysis Transplantation1997;12(10):2140‐3. [MEDLINE: 9351079] ">Castro 1997</a>; <a href="./references#CD005019-bbs2-0028" title="ChengIKP , LiPWC , JanusED , TangCSO , ChanTM , LoCY . Comparative efficacy of gemfibrozil (G) and simvastatin (S) in the treatment of hyperlipidaemia in renal transplant recipients (RT) ‐ a randomised prospective study [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:383. [CENTRAL: CN‐00509131] ">Cheng 1995</a>; <a href="./references#CD005019-bbs2-0031" title="Gonzalez‐MolinaM , CabelloM . Effect of diet, exercise and HMG‐CoA reductase on hypercholesterolaemia in renal transplant patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):1040. [CENTRAL: CN‐00260885] Gonzalez‐MolinaM , CabelloM , TinahonesF , BurgosD , LilloJ , SoriguerF , et al. Hyperlipoproteinemia in renal transplant patients: Effect of hypocaloric diet, exercise and HMG‐CoA reductase inhibition. Nefrologia1996;16(4):359‐64. [EMBASE: 1996302763] ">Gonzalez‐Molina 1996</a>; <a href="./references#CD005019-bbs2-0039" title="LalSM , HewettJE , PetroskiGF , VanStoneJC , RossG . Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open‐labeled crossover trial. American Journal of Kidney Diseases1995;25(4):616‐22. [MEDLINE: 7702060] LalSM , PetroskiGF , HewettJE , VanStoneJC , RossG . Long term lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no:76P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):946. [CENTRAL: CN‐00484737] LalSM , PetroskiGF , HewettJE , VanStoneJC , RossG . Three year follow up data on the lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no: 372]. Journal of the American Society of Nephrology1995;6(3):1100. [CENTRAL: CN‐00484738] LalSM , VanStoneJ , RossGJr . Lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract]. Journal of the American Society of Nephrology1992;3(3):866. [CENTRAL: CN‐00461132] ">Lal 1992</a>; <a href="./references#CD005019-bbs2-0040" title="LalSM , RossG . Lipid lowering effects of gemfibrozil and pravastatin with or without cholestyramine in diabetic renal transplant patients [abstract no: A3342]. Journal of the American Society of Nephrology1996;7(9):1915. [CENTRAL: CN‐00775367] ">Lal 1996</a>; <a href="./references#CD005019-bbs2-0041" title="LalSM , HabibS . Lipid lowering effects of niacin and lovastatin given alone or with cholestyramine in renal transplant patients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):683A. [CENTRAL: CN‐00446257] ">Lal 1998</a>; <a href="./references#CD005019-bbs2-0052" title="RodriguezAP , DeBonisE , GonzalezPJ , TorresA , PerezL , DominguezML , et al. Treatment of hyperlipidemia after renal transplantation: Comparative effect of lovastatin and omega‐3 fatty acids. Nefrologia1997;17(1):49‐54. [EMBASE: 1997130521] ">Rodriguez 1997</a>; <a href="./references#CD005019-bbs2-0055" title="VasquezEM , SifontisN , JacobssenV , TestaG , SankaryH , BenedettiE . Simvastatin for prevention of bone loss following renal transplantation [abstract no: P284]. Transplantation2004;78(2 Suppl):293. [CENTRAL: CN‐00509537] ">Vasquez 2004</a>; <a href="./references#CD005019-bbs2-0056" title="WhiteM , HanesD , WilandA , KlassenD , Hoen‐SaricE , SchweitzerE , et al. Long‐term treatment of hyperlipidemia in transplant recipients with pravastatin and gemfibrozil [abstract]. 15th Annual Meeting American Society of Transplant Physicians (ASTP);1996 May 10‐14; Chicago (ILL). 1996. ">White 1996</a>); seven did not use a randomised study design (<a href="./references#CD005019-bbs2-0026" title="CaponeD , StanzialeP , GentileA , ImperatoreP , PellegrinoT , BasileV . Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. American Journal of Nephrology1999;19(3):411‐5. [MEDLINE: 10393380] ">Capone 1999</a>; <a href="./references#CD005019-bbs2-0043" title="LopauK , SpindlerK , WannerC . Effects of pravastatin treatment on blood pressure regulation after renal transplantation. Kidney &amp; Blood Pressure Research2006;29(6):329‐37. [MEDLINE: 17124431] ">Lopau 2006</a>; <a href="./references#CD005019-bbs2-0044" title="MarkellMS , SumraniN , BrownCD , HongJH , SommerBG , FriedmanEA . Effect of hypercholesterolemia and lipid‐lowering therapy on glomerular filtration rate in renal transplants [abstract no: 1808]. Journal of the American Society of Nephrology1995;6(3):1103. [CENTRAL: CN‐00484981] ">Markell 1995</a>; <a href="./references#CD005019-bbs2-0045" title="NartA , UsluA , BozkayaG , AykasA , DoganM , KaracaB . A prudent algorithm for hyperlipoproteinemia in renal transplant recipients. Transplantation Proceedings2009;41(2):751‐5. [MEDLINE: 19328972] ">Nart 2009</a>; <a href="./references#CD005019-bbs2-0046" title="NicholsonPG , RavalDD , BehrensMT , WeirMR . A prospective cross over trial to compare the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients [abstract no: 76P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):952. [CENTRAL: CN‐00485241] ">Nicholson 1993</a>; <a href="./references#CD005019-bbs2-0053" title="RuizMC , MorenoJM , RuizN , VargasF , AsensioC , OsunaA . Effect of statin treatment on oxidative stress and renal function in renal transplantation. Transplantation Proceedings2006;38(8):2431‐3. [MEDLINE: 17097958] ">Ruiz 2006</a>; <a href="./references#CD005019-bbs2-0054" title="TurkS , YildizA , TukekT , AkkayaV , ArasU , TurkmenA , et al. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo‐controlled study. International Urology &amp; Nephrology2001;32(4):713‐6. [MEDLINE: 11989571] ">Turk 2001</a>); one was terminated (<a href="./references#CD005019-bbs2-0050" title="RendersL . Cardiovascular events in renal Transplant recipients with low LDL‐cholesterol receiving tacrolimus in combination with the statin fluvastatin [CRANOC]. www.clinicaltrials.gov/ct2/show/NCT00223041 (accessed 19 December 2013). ">Renders 2010</a>); six were of short duration (<a href="./references#CD005019-bbs2-0036" title="KovarikJM , HartmannS , BerthierS , HubertM , RordorfC , SombergK . Statin therapy in renal transplant patients receiving everolimus: screening for clinical and pharmacokinetic drug interactions [abstract no:187]. American Journal of Transplantation2002;2(Suppl 3):185. [CENTRAL: CN‐00416055] ">Kaplan‐251 2001</a>; <a href="./references#CD005019-bbs2-0037" title="KasiskeBL , TortoriceKL , Heim‐DuthoyKL , GoryanceJM , RaoKV . Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation1990;49(1):95‐100. [MEDLINE: 2105548] ">Kasiske 1990</a>; <a href="./references#CD005019-bbs2-0038" title="KliemV , WannerC , EisenhauerT , OlbrichtCJ , DollR , BoddaertM , et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplantation Proceedings1996;28(6):3126‐8. [MEDLINE: 8962211] ">Kliem 1996</a>; <a href="./references#CD005019-bbs2-0048" title="OlbrichtC , WannerC , EisenhauerT , ChristiansU , KliemV , O'GradyP , et al. Pravastatin and lovastatin pharmacokinetics and pharmacodynamics in renal transplant patients receiving cyclosporine [abstract]. Journal of the American Society of Nephrology1995;6(3):1061. [CENTRAL: CN‐00485312] OlbrichtC , WannerC , EisenhauerT , KliemV , DollR , BoddaertM , et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses. Clinical Pharmacology &amp; Therapeutics1997;62(3):311‐21. [MEDLINE: 9333107] ">Olbricht 1997</a>; <a href="./references#CD005019-bbs2-0049" title="RaiolaP , ManzoM , SaggeseA . Interaction of cyclosporine and fluvastatin with and without niacin in renal transplant patients with dyslipoproteinemia [abstract no: A3368]. Journal of the American Society of Nephrology1996;7(9):1920. [CENTRAL: CN‐00775265] ">Raiola 1996</a>; <a href="./references#CD005019-bbs2-0051" title="RigattoO , RushD , PerryY , WalkerS , BoseR , BolliP . Cholesterol reduction in cyclosporine‐treated renal transplant patients: effect on platelet‐derived growth factor levels and platelet activation. Transplantation Proceedings1997;29(6):2591‐2. [MEDLINE: 9290755] ">Rigatto 1997</a>); and one study was conducted in children (<a href="./references#CD005019-bbs2-0031" title="Gonzalez‐MolinaM , CabelloM . Effect of diet, exercise and HMG‐CoA reductase on hypercholesterolaemia in renal transplant patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):1040. [CENTRAL: CN‐00260885] Gonzalez‐MolinaM , CabelloM , TinahonesF , BurgosD , LilloJ , SoriguerF , et al. Hyperlipoproteinemia in renal transplant patients: Effect of hypocaloric diet, exercise and HMG‐CoA reductase inhibition. Nefrologia1996;16(4):359‐64. [EMBASE: 1996302763] ">Gonzalez‐Molina 1996</a>). </p> </section> </section> <section id="CD005019-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>Based on the current standards, the risk for bias in many of the included studies was high (<a href="#CD005019-fig-0002">Figure 2</a>; <a href="#CD005019-fig-0003">Figure 3</a>). Notably however, most data for analyses were obtained from a single, large, well‐conducted study in which all items of risk were low except sequence generation and allocation concealment (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>). </p> <div class="figure" id="CD005019-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005019-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005019-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005019-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005019-sec-0070"> <h4 class="title">Allocation</h4> <p>Random sequence generation was adequate in &lt; 25% of studies (<a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>) and allocation concealment was adequate in &lt; 25% of studies (<a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>). </p> </section> <section id="CD005019-sec-0071"> <h4 class="title">Blinding</h4> <p>Participants and personnel were blinded in 50% of studies (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0002" title="ArnadottirM , ErikssonLO , GermershausenJI , ThysellH . Low‐dose simvastatin is a well‐tolerated and efficacious cholesterol‐lowering agent in ciclosporin‐treated kidney transplant recipients: double‐blind, randomized, placebo‐controlled study in 40 patients. Nephron1994;68(1):57‐62. [MEDLINE: 7991041] ">Arnadottir 1994</a>; <a href="./references#CD005019-bbs2-0007" title="HausbergM , BarenbrockM , StamF , KoschM , KistersK , HeidenreichS , et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):677A. [CENTRAL: CN‐00445668] HausbergM , BarenbrockM , StamF , KoschM , KistersK , SpiekerC , et al. HMG‐CoA‐reductase inhibitors improve brachial artery flow‐mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation1999;14(9):A282. [CENTRAL: CN‐00484274] HausbergM , KoschM , StamF , HeidenreichS , KistersK , RahnKH , et al. Effect of fluvastatin on endothelium‐dependent brachial artery vasodilation in patients after renal transplantation. Kidney International2001;59(4):1473‐9. [MEDLINE: 11260410] KoschM , BarenbrockM , HausbergM . Sustained beneficial effect of a therapy with the HMG‐Co‐A‐reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren‐und Hochdruckkrankheiten2004;33(10):577‐83. [EMBASE: 2004495206] KoschM , BarenbrockM , SuwelackB , SchaeferRM , RahnKH , HausbergM . Effect of a 3‐year therapy with the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase‐inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases2003;41(5):1088‐96. [MEDLINE: 12722044] ">Hausberg 2001</a>; <a href="./references#CD005019-bbs2-0008" title="KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ . Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]. Transplantation2000;69(8 Suppl):S225. [CENTRAL: CN‐00446023] KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ , BastaniB . The effects of lipid‐lowering agents on acute renal allograft rejection. Transplantation2001;72(2):223‐7. [MEDLINE: 11477342] ">Kasiske 2001</a>; <a href="./references#CD005019-bbs2-0010" title="LepreF , RigbyR , HawleyC , SaltissiD , BrownA , WalshZ . A double‐blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clinical Transplantation1999;13(6):520‐5. [MEDLINE: 10617243] ">Lepre 1999</a>; <a href="./references#CD005019-bbs2-0015" title="SahuK , SharmaR , GuptaA . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation2001;15(3):173‐5. [MEDLINE: 11389707] SharmaRK , SahuKM , GuptaA , GulatiS , AgarwalDK , KumarA , et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation1999;14(9):A288. [CENTRAL: CN‐00485837] ">Sahu 2001</a>; <a href="./references#CD005019-bbs2-0016" title="GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00671773] GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind, randomized placebo controlled study [abstract no: 1439]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00615908] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416585] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind randomized placebo controlled study [abstract no:3367]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416586] SantosAF , KeitelE , BittarAE , NeumannJ . Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double‐blind, randomized, placebo‐controlled study [abstract no: PO601]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00465849] SantosAF , KeitelE , BittarAE , NeumannJ , FonsecaN , SporlederH , et al. Simvastatin effect on NK cells activity in vivo: a double‐blind randomized, placebo‐controlled study. Transplantation Proceedings2002;34(7):2874‐5. [MEDLINE: 12431639] SantosAF , KeitelE , BittarAE , NeumannJ , FuchsFD , GoldaniJC , et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double‐blind, randomized, placebo‐controlled study. Transplantation Proceedings2001;33(1‐2):1194‐5. [MEDLINE: 11267254] ">Santos 2001</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>; <a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>) while outcome assessors were blinded in &lt; 25% of studies (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>; <a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>). </p> </section> <section id="CD005019-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Completeness of outcome reporting and intention to treat analysis method was followed in &lt; 25% of included studies (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0006" title="CofanF , GilabertR , ZambonD , NunezI , RosE , CofanM , et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings2002;34(1):384‐8. [MEDLINE: 11959338] CofanF , ZambonD , LagunaJC , CasalsE , RosE , CofanM , et al. Pravastatin improves low‐density lipoprotein oxidation in renal transplantation. Transplantation Proceedings2002;34(2):389‐91. [MEDLINE: 11959339] ">Cofan 2002</a>; <a href="./references#CD005019-bbs2-0015" title="SahuK , SharmaR , GuptaA . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation2001;15(3):173‐5. [MEDLINE: 11389707] SharmaRK , SahuKM , GuptaA , GulatiS , AgarwalDK , KumarA , et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation1999;14(9):A288. [CENTRAL: CN‐00485837] ">Sahu 2001</a>; <a href="./references#CD005019-bbs2-0018" title="SharifA , RavindranV , MooreR , BaboolalK . The effects of rosuvastatin on 51CR‐EDTA measured glomerular filtration rate and urinary albumin excretion in non‐diabetic renal transplant recipients [abstract no: 1386]. Transplantation2008;86(2S):466. [CENTRAL: CN‐00766701] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta‐cell function in nondiabetic renal transplant recipients. American Journal of Transplantation2009;9(6):1439‐45. [MEDLINE: 19459810] SharifA , RavindranV , MooreR , DunseathG , LuzioS , OwensD , et al. The effects of rosuvastatin on insulin sensitivity and secretion in non‐diabetic renal transplant recipients [abstract no: 611]. Transplantation2008;86(2S):214. [CENTRAL: CN‐00766702] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non‐diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation2009;9(Suppl 2):208. [CENTRAL: CN‐00775209] SharifA , RavindranV , MooreR , LuzioS , DunseathG , OwensD , et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes2009;1:A92‐3. [EMBASE: 70212602] ">Sharif 2009</a>; ; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>). </p> </section> <section id="CD005019-sec-0073"> <h4 class="title">Selective reporting</h4> <p>Adverse events were assessed systematically in only eight studies (36%) (<a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a>; <a href="./references#CD005019-bbs2-0002" title="ArnadottirM , ErikssonLO , GermershausenJI , ThysellH . Low‐dose simvastatin is a well‐tolerated and efficacious cholesterol‐lowering agent in ciclosporin‐treated kidney transplant recipients: double‐blind, randomized, placebo‐controlled study in 40 patients. Nephron1994;68(1):57‐62. [MEDLINE: 7991041] ">Arnadottir 1994</a>; <a href="./references#CD005019-bbs2-0012" title="MelchorJL , GracidaC . Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplantation Proceedings1998;30(5):2054. [MEDLINE: 9723390] ">Melchor 1998</a>; <a href="./references#CD005019-bbs2-0014" title="RendersL , Mayer‐KadnerI , KochC . Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients. Nephrology Dialysis Transplantation2001;16(1):141‐6. [MEDLINE: 11209008] RendersL , Mayer‐KadnerI , KochC , BurkhardtK , VeelkenR , SchmiederR , et al. Cerivastatin and atorvastatin: efficacy, safety and drug‐interaction of the new HMG‐COA reductase inhibitors in renal transplant patients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):694A. [CENTRAL: CN‐00447381] ">Renders 2001</a>; <a href="./references#CD005019-bbs2-0016" title="GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00671773] GarciaV , BittarA , KeitelE , NeumannJ , SaitovitchD , SantosA . Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind, randomized placebo controlled study [abstract no: 1439]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CENTRAL: CN‐00615908] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is cyclosporin microemulsion increasing the lipid‐lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416585] SantosAF , KeitelE , BittarA , NeumannJ , SaitovichD , SeeligDC , et al. Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double‐blind randomized placebo controlled study [abstract no:3367]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416586] SantosAF , KeitelE , BittarAE , NeumannJ . Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double‐blind, randomized, placebo‐controlled study [abstract no: PO601]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00465849] SantosAF , KeitelE , BittarAE , NeumannJ , FonsecaN , SporlederH , et al. Simvastatin effect on NK cells activity in vivo: a double‐blind randomized, placebo‐controlled study. Transplantation Proceedings2002;34(7):2874‐5. [MEDLINE: 12431639] SantosAF , KeitelE , BittarAE , NeumannJ , FuchsFD , GoldaniJC , et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double‐blind, randomized, placebo‐controlled study. Transplantation Proceedings2001;33(1‐2):1194‐5. [MEDLINE: 11267254] ">Santos 2001</a>; <a href="./references#CD005019-bbs2-0017" title="SeronD , OppenheimerF , PallardoLM , LauzuricaR , ErrastiP , Gomez‐HuertasE , et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double‐blind, placebo‐controlled trial. Transplantation2008;86(1):82‐7. [MEDLINE: 18622282] ">Seron 2008</a>; <a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>; <a href="./references#CD005019-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract no: SA‐P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437a. [CENTRAL: CN‐00444305] ">UK‐HARP‐1 2005</a>). </p> </section> </section> <section id="CD005019-sec-0074"> <h3 class="title" id="CD005019-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD005019-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD005019-sec-0075"> <h4 class="title">Statin versus placebo or no treatment</h4> <p>Based largely on data from a single high‐quality study, statins may reduce cardiovascular mortality (<a href="./references#CD005019-fig-0004" title="">Analysis 1.1</a> (4 studies, 2322 participants): RR 0.68, 95% CI 0.45 to 1.01; I² = 0%); major cardiovascular events (<a href="./references#CD005019-fig-0006" title="">Analysis 1.3</a> (1 study, 2102 participants): RR 0.84, 95% CI 0.66 to 1.06); fatal or non‐fatal myocardial infarction (<a href="./references#CD005019-fig-0007" title="">Analysis 1.4</a> (1 study, 2102 participants): RR 0.70, 95% CI 0.48 to 1.01). Overall, in absolute terms, treating 1000 adults with a functioning kidney transplant with a statin for one year may prevent two major cardiovascular events and two cardiovascular deaths (<a href="./full#CD005019-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Statin treatment had uncertain effects on all‐cause mortality (<a href="./references#CD005019-fig-0005" title="">Analysis 1.2</a> (6 studies, 2760 participants): RR 1.08, 95% CI 0.63 to 1.83; I² = 9%) and fatal or non‐fatal stroke (<a href="./references#CD005019-fig-0008" title="">Analysis 1.5</a> (1 study, 2102 participants): RR 1.18, 95% CI 0.85 to 1.63). There was no significant heterogeneity in analyses that contained more than one study. </p> <p>Statins had uncertain effects on adverse events: creatine kinase elevation (<a href="./references#CD005019-fig-0009" title="">Analysis 1.6</a> (3 studies, 2322 participants): RR 0.86, 95% CI 0.39 to 1.89; I² = 0%); liver enzyme elevation (<a href="./references#CD005019-fig-0010" title="">Analysis 1.7</a> (4 studies, 608 participants): RR 0.62. 95% CI 0.33 to 1.19 I² = 0%); withdrawal due to adverse events (<a href="./references#CD005019-fig-0011" title="">Analysis 1.8</a> (9 studies, 2810 participants): RR 0.89, 95% CI 0.74 to 1.06; I² = 0%); and cancer (<a href="./references#CD005019-fig-0012" title="">Analysis 1.9</a> (1 study, 2094 participants): RR 0.94, 95% CI 0.82 to 1.07). There was no significant heterogeneity in these analyses. </p> <p>Statins significantly reduced serum total cholesterol (<a href="./references#CD005019-fig-0013" title="">Analysis 1.10</a> (12 studies, 3070 participants): MD ‐42.43 mg/dL, 95% CI ‐51.22 to ‐33.65; I² = 87%); LDL cholesterol (<a href="./references#CD005019-fig-0014" title="">Analysis 1.11</a> (11 studies, 3004 participants): MD ‐43.19 mg/dL, 95% CI ‐52.59 to ‐33.78; I² = 84%); lowered HDL cholesterol (<a href="./references#CD005019-fig-0015" title="">Analysis 1.12</a> (11 studies, 3005 participants): MD ‐5.69 mg/dL, 95% CI ‐10.35 to ‐1.03; I² = 89%); and serum triglycerides (<a href="./references#CD005019-fig-0016" title="">Analysis 1.13</a> (11 studies, 3012 participants): MD ‐27.28 mg/dL, 95% CI ‐34.29 to ‐20.27; I² = 15%). There was marked heterogeneity in the analyses for total cholesterol, LDL cholesterol and HDL cholesterol levels. </p> <p>Statins had uncertain effects on kidney function: ESKD (<a href="./references#CD005019-fig-0017" title="">Analysis 1.14</a> (6 studies, 2740 participants): RR 1.14, 95% CI 0.94 to 1.37; I² = 0%); acute allograft rejection (<a href="./references#CD005019-fig-0018" title="">Analysis 1.15</a> (5 studies, 582 participants): RR 0.88, 95% CI 0.61 to 1.28; I² = 39%); proteinuria (<a href="./references#CD005019-fig-0019" title="">Analysis 1.16</a> (2 studies, 136 participants): MD ‐0.04 g/24 h, 95% CI ‐0.17 to 0.25; I² = 0%); and GFR (<a href="./references#CD005019-fig-0020" title="">Analysis 1.17</a> (1 study, 62 participants): MD ‐1.00 mL/min, 95% CI ‐9.96 to 7.96). </p> </section> <section id="CD005019-sec-0076"> <h4 class="title">Statin versus statin</h4> <p>Due to heterogeneity in comparisons, data directly comparing differing statin regimens could not be meta‐analysed. </p> <p> <ul id="CD005019-list-0008"> <li> <p><a href="./references#CD005019-bbs2-0004" title="CastelaoAM , GrinoJM , AndresE , GilvernetS , SeronD , CastineirasMJ , et al. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplantation Proceedings1993;25(1 Pt 2):1043‐6. [MEDLINE: 8442035] Martinez‐CastelaoA , GrinyoJM , Gil‐VernetS , SeronD , CastineirasMJ , RamosR , et al. Lipid‐lowering long‐term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplantation Proceedings2002;34(1):398‐400. [MEDLINE: 11959343] ">Castelao 1993</a> compared lovastatin and simvastatin head‐to‐head in reducing lipid parameters alone for 12 months. This study concluded that both agents had similar effects in decreasing lipid parameters (total cholesterol 193 mg/dL versus 197 mg/dL at the end of 12 months). </p> </li> <li> <p><a href="./references#CD005019-bbs2-0013" title="RaiolaP , ManzoM , SaggeseA . Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):693A. [CENTRAL: CN‐00447330] ">Raiola 1998</a> compared atorvastatin 10 mg/d to fluvastatin 20 mg/d for eight weeks (30 participants) and there was significantly lower LDL cholesterol and serum triglyceride level with atorvastatin. </p> </li> <li> <p><a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a> compared simvastatin 10 mg/d, pravastatin 20 mg/d and placebo among 57 kidney transplant patients. Both statins reduced lipid parameters and incidence of acute allograft rejection at a similar rate. </p> </li> <li> <p><a href="./references#CD005019-bbs2-0022" title="VergoulasG , MiserlisG , GakisD , ImvriosG , PapagiannisA , PapanikolaouV , et al. Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]. Nephrology Dialysis Transplantation1999;14(9):A312. [CENTRAL: CN‐00486302] ">Vergoulas 1999</a> compared lovastatin 20 mg/d with fluvastatin 40 mg/d among 50 kidney transplant recipients. The end of treatment total cholesterol level was lower with lovastatin than fluvastatin both at three months and one year follow‐up. </p> </li> <li> <p>In a randomised cross‐over study (20 participants), simvastatin 10 mg/d was compared with simvastatin 20 mg/d (<a href="./references#CD005019-bbs2-0005" title="CelikA , UnsalA , MutafI , HabifS , OkE , BayindirO . Which dosage of simvastatin in renal transplant patients?. Nephron2000;84(1):81‐2. [MEDLINE: 10644914] ">Celik 2000a</a>). Even though no difference was noted among the lipid parameters between these two groups, simvastatin 20 mg/d had higher occurrence of serious side effects (3) warranting drug withdrawal. </p> </li> </ul> </p> </section> <section id="CD005019-sec-0077"> <h4 class="title">Analysis of heterogeneity</h4> <p>We found significant heterogeneity in the meta‐analyses for end of study cholesterol, LDL cholesterol, HDL cholesterol and triglycerides, which we explored using pre‐specified subgroup analyses. </p> <p>For total cholesterol, statin type was the only identifiable modifier of treatment effect we found, explaining 60% of the heterogeneity. Simvastatin provided the greatest reduction in total cholesterol (5 studies, 371 participants: MD ‐55.57 mg/dL, 95% CI ‐69.17 to ‐41.97) and fluvastatin the least (4 studies, 2506 participants: ‐31.48 mg/dL, 95% CI ‐37.02 to ‐25.95). Insufficient data meant that we were unable to perform multivariate meta‐regression analyses to determine the effect of dose and statin type on cholesterol levels and therefore, we were unable to determine whether differences in statin agents were due to doses used, or otherwise. </p> <p>Dose, age of participants, proportion with diabetes, adequacy of allocation concealment, and serum cholesterol at baseline did not modify treatment effects on serum cholesterol levels. Subgroup analyses for statin type, dose, age, diabetes, allocation concealment or baseline cholesterol did not identify sources of heterogeneity for end of treatment effects of statins on LDL cholesterol or triglyceride levels. For HDL cholesterol, baseline serum cholesterol modified treatment effects of statins; in people with lower serum total cholesterol (&lt; 230 mg/dL) statins reduced HDL cholesterol (MD ‐15.2 mg/dL, 95% CI ‐20.9 to ‐9.6) but not in populations with higher baseline serum total cholesterol (MD ‐0.1 mg/dL, 95% CI ‐4.9 to 4.6) explaining 80% of the heterogeneity in treatment effects observed among studies. </p> <p>Subgroup analyses for allograft rejection could not be performed due to an insufficient number of studies. </p> </section> <section id="CD005019-sec-0078"> <h4 class="title">Publication bias</h4> <p>Insufficient numbers of studies had data that could be included to allow formal evaluation of potential publication bias for clinical outcomes (cardiovascular events and mortality). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005019-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005019-sec-0079"></div> <section id="CD005019-sec-0080"> <h3 class="title" id="CD005019-sec-0080">Summary of main results</h3> <p>This updated review found that in data derived largely from the well‐conducted <a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a> study, statins (generally at a simvastatin dose equivalent to 10 mg/d) are likely to reduce cardiovascular events, cardiovascular death, and myocardial infarction for recipients of a kidney transplant, although the magnitude of this effect remains uncertain. While point estimates suggest the potential for benefit with statin treatment are consistent with the benefits observed in people with CKD not treated with dialysis, confidence intervals were wide and included the possibility of no effect. Statin treatment has uncertain effects on death overall and fatal or non‐fatal stroke in transplant patients. The data are particularly incomplete for treatment‐related harms of statins in people with a functioning kidney transplant as data are limited by lack of systematic assessment and reporting of treatment‐related toxicity. Statins have uncertain effects on kidney function and transplant rejection. Statin therapy clearly reduces serum cholesterol concentrations on average by 42 mg/dL (1.1 mmol/L) as well as triglyceride concentrations, although treatment effects on cholesterol levels are inconsistent between studies. Data comparing different statins or different doses of statins were sparse in adults who have a functioning kidney transplant. </p> </section> <section id="CD005019-sec-0081"> <h3 class="title" id="CD005019-sec-0081">Overall completeness and applicability of evidence</h3> <p>Importantly, outcome data for statins remain scant for several important clinical settings. Notably the doses of statins in the available studies were relatively low (10 mg simvastatin equivalent) and direct comparative data comparing different statin doses were sparse. Studies of higher doses or combinations of statin with other agents that lower cholesterol absorption (such as ezetimibe, as used in the recent <a href="./references#CD005019-bbs2-0098" title="BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377:2181‐92. ">SHARP 2011</a> study) compared to placebo are warranted, although systematic ascertainment and reporting of treatment‐related toxicity in such studies would be essential. Similarly, it is also unclear whether treatment benefits from statins were dependent on reductions in serum cholesterol ‐ as insufficient studies reporting cardiovascular and mortality outcomes also reported changes in cholesterol levels with treatment. </p> <p>Second, sufficient data were not available to determine the relative benefits of statins in the primary prevention of cardiovascular events (treatment of individuals without clinically evident cardiovascular disease) as compared to secondary prevention (treating individuals with established cardiovascular disease) as too few studies were available to summarise data for these specific populations. It should be noted that treatment effects for mortality and cardiovascular events were consistent across all studies suggesting similar treatment effects irrespective of presence of vascular disease (although analyses for consistently were underpowered due to the small number of studies reporting events). </p> <p>Third, data were limited by the relative paucity of available studies specifically conducted to evaluate statins in people with a functioning kidney transplant. Importantly, data for cardiovascular outcomes and mortality were almost entirely reliant on the large well‐conducted <a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a> study in people with stable kidney function more than six months after kidney or combined kidney and pancreas transplantation. Studies were frequently underpowered for clinical outcomes or did not systematically ascertain outcome events, such that outcome measurement is likely to be less reliable. Additional data from further studies in transplantation would improve our confidence in the treatment estimates for statins and may change the treatment estimates observed (in other words, improve the quality of the currently available evidence). </p> <p>One study only enrolled living‐related transplant recipients (<a href="./references#CD005019-bbs2-0015" title="SahuK , SharmaR , GuptaA . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation2001;15(3):173‐5. [MEDLINE: 11389707] SharmaRK , SahuKM , GuptaA , GulatiS , AgarwalDK , KumarA , et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation1999;14(9):A288. [CENTRAL: CN‐00485837] ">Sahu 2001</a>) and another only included deceased donor‐related transplant recipients (<a href="./references#CD005019-bbs2-0009" title="KatznelsonS , WilkinsonAH , DanovitchGM , WangXM , ChiaD , KobashigawaJA , et al. Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]. Journal of the American Society of Nephrology1994;5(3):1017. [CENTRAL: CN‐00601908] KatznelsonS , WilkinsonAH , DanovitchGM , WangXM , ChiaD , OzawaM , et al. The impact of pravastatin on the incidence of acute rejection after renal transplantation and on cellular immune function [abstract]. 14th Annual Meeting American Society of Transplant Physicians (ASTP);1995 May 10‐14; Chicago (USA). 1995. KatznelsonS , WilkinsonAH , KobashigawaJA , WangXM , ChiaD , OzawaM , et al. The effect of pravastatin on acute rejection after kidney transplantation‐‐a pilot study. Transplantation1996;61(10):1469‐74. [MEDLINE: 8633373] ">Katznelson 1996</a>). The remainder included mixed populations of both deceased and living donors. Of note, separate results for these different subgroups were not detailed in the reports for <a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>, <a href="./references#CD005019-bbs2-0008" title="KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ . Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]. Transplantation2000;69(8 Suppl):S225. [CENTRAL: CN‐00446023] KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ , BastaniB . The effects of lipid‐lowering agents on acute renal allograft rejection. Transplantation2001;72(2):223‐7. [MEDLINE: 11477342] ">Kasiske 2001</a> or <a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>. Thus, whether statins have beneficial effects on these separate populations (recipients of a transplant from a deceased or living donor) could not be studied. </p> <p>Statins have unclear effects on the development of ESKD. These data seem to mirror the uncertainty of treatment effects on kidney function we have observed with statin use in people with earlier stages of CKD not on dialysis (<a href="./references#CD005019-bbs2-0092" title="NavaneethanSD , PansiniF , PerkovicV , MannoC , PellegriniF , JohnsonDW , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007784] ">Navaneethan 2009a</a>). Notably, extended follow‐up of <a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a> showed no difference between statins and placebo groups for kidney outcomes, such as doubling of serum creatinine or graft loss (<a href="./references#CD005019-bbs2-0071" title="FellströmB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] ">Fellstrom 2004</a>). </p> <p>Based on the current data, the available evidence for statins is largely generalizable to people with stable kidney function who have had a kidney transplant and are at risk of cardiovascular disease. Additional data for kidney transplant recipients who have had a recent acute cardiovascular event (that is, myocardial infarction) are currently lacking, as fewer than 5% of the <a href="./references#CD005019-bbs2-0001" title="AbediniS , HolmeI , FellstromB , JardineA , ColeE , MaesB , et al. Cerebrovascular events in renal transplant recipients. Transplantation2009;87(1):112‐7. [MEDLINE: 19136900] AbediniS , HolmeI , MarzW , WeihrauchG , FellstromB , JardineA , et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN2009;4(7):1246‐54. [MEDLINE: 19541816] AbediniS , JardineA , FellstromB , HoldaasH . Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation2009;9(Suppl 2):207. [CENTRAL: CN‐00763910] AbediniS , JardineA , FellstromB , MeinitzerA , MarzW , BermannG , et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F‐FC149]. Journal of the American Society of Nephrology2006;17(Abstracts):68A. [CENTRAL: CN‐00689307] AbediniS , MeinitzerA , HolmeI , MarzW , WeihrauchG , FellstromB , et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all‐cause mortality in renal transplant recipients. Kidney International2010;77(1):44‐50. [MEDLINE: 19847152] FellstromB , AbediniS , HoldaasH , JardineAG , StafflerB , GimpelewiczC , et al. No detrimental effect on renal function during long‐term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation2006;20(6):732‐9. [MEDLINE: 17100723] FellstromB , HoldaasH , JardineA , ColeE , NybergG , Grohagen‐RiskaC , et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):187A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on graft losses and renal function in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):10A. FellstromB , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation ‐ experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):185A. FellstromB , HoldaasH , JardineA , HolmeI , NybergG , Gronhagen‐RiskaC , et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):236. [CENTRAL: CN‐00445309] FellstromB , HoldaasH , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International2004;66(4):1549‐55. [MEDLINE: 15458450] FellstromB , HoldaasH , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation2005;79(2):205‐12. [MEDLINE: 15665769] FellstromB , HoldassH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation ‐ experience from the ALERT trial [abstract]. Transplantation2004;78(2 Suppl):57. [CENTRAL: CN‐00509185] FellstromB , JardineAG , SoveriI , ColeE , Gronhagen‐RiskaC , NeumayerHH , et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation2005;79(9):1160‐3. [MEDLINE: 15880062] FellstromB , JardineAG , SoveriI , ColeE , NeumayerHH , MaesB , et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation2005;5(8):1986‐91. [MEDLINE: 15996249] FellstromBC , HoldaasH , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation2004;4(Suppl 8):261. [CENTRAL: CN‐00509187] HoldaasH , AbediniS , JardineA , MaesB , MärzW , FellstromB . Parathyroid hormone and phosphate ‐ risk factors for post‐transplant cardiovascular disease? [abstract no: TH‐FC084]. Journal of the American Society of Nephrology2006;17(Abstracts):19A. [CENTRAL: CN‐00615900] HoldaasH , AsbergA , EdvardsenC , HartmannA . Statins endothelial function in renal transplant recipients ‐ a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):894A. [CENTRAL: CN‐00776306] HoldaasH , FellstromB , ColeE , NybergG , OlssonAG , PedersenTR , et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation2005;5(12):2929‐36. [MEDLINE: 16303007] HoldaasH , FellstromB , HolmeI , NybergG , FauchaldP , JardineA , et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk2001;8(2):63‐71. [MEDLINE: 11324372] HoldaasH , FellstromB , JardinA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: M‐PO50032]. Nephrology2005;10(Suppl):A88. [CENTRAL: CN‐00615876] HoldaasH , FellstromB , JardineA , ColeE , MaesB , NybergG , et al. Risk factors for late new‐onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation2005;5(Suppl 11):328. [CENTRAL: CN‐00757934] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipid‐lowering therapy should be started early in the post‐transplant period [abstract no: F‐PO569]. Journal of the American Society of Nephrology2003;14(Nov):185A. [CENTRAL: CN‐00550528] HoldaasH , FellstromB , JardineA , ColeE , NybergG , Gronhagen‐RiskaC , et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow‐up [abstract no: SO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v3. [CENTRAL: CN‐00601991] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology2004;15(Oct):881A. [CENTRAL: CN‐00550529] HoldaasH , FellstromB , JardineA , GimpelewiczC , StafflerB , LoganJ , et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA‐PO1048]. Journal of the American Society of Nephrology2004;15(Oct):527A. [CENTRAL: CN‐00550531] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , FauchaldP , et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):442. [CENTRAL: CN‐00445757] HoldaasH , FellstromB , JardineA , HolmeI , NybergG , et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):237. [CENTRAL: CN‐00445756] HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology2005;16:72A. HoldaasH , FellstromB , JardineA , NybergG , Gronhagen‐RiskaC , MadsenS , et al. No detrimental effect on renal function during long‐term use of fluvastatin [abstract]. Transplantation2004;78(2 Suppl):327. [CN‐00509236] HoldaasH , FellstromB , JardineAG , ColeE , NybergG , Gronhagen‐RiskaC , et al. Lipids as risk factors for cardiac events after renal transplantation ‐ experience from the ALERT trial [abstract no: SU‐PO590]. Journal of the American Society of Nephrology2003;14(Nov):662A. [CENTRAL: CN‐00550542] HoldaasH , FellstromB , JardineAG , HolmeI , NybergG , FauchaldP , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‐controlled trial. Lancet2003;361(9374):2024‐31. [MEDLINE: 12814712] HoldaasH , FellstromB , JardineAG , NybergG , Gronhagen‐RiskaC , MadsenS , et al. Beneficial effect of early initiation of lipid‐lowering therapy following renal transplantation. Nephrology Dialysis Transplantation2005;20(5):974‐80. [MEDLINE: 15784644] HoldaasH , FellstromB , MaesB , ColeE , JardineA . Impact of hemoglobin levels on graft function, cardiac events and all‐cause mortality after renal transplantation [abstract no: F‐PO1502]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):443A. [CENTRAL: CN‐00756929] HoldaasH , JardineA , HolmeI , BrekkeIB , WheelerDC , OstraatO , et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome (Italy). 2000. [CENTRAL: CN‐00527128] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International2001; Vol. 60, issue 5:1990‐7. [MEDLINE: 21561172] HolmeI , FellstromB , JardineA , HoldaasH . Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis2010;208(1):234‐9. [MEDLINE: 19596331] JardineA , WeihrauchG , MaerzW , FellstromB , BermannG , HoldaasH . Osteoprotegerin ‐ a novel risk factor post‐transplant cardiovascular disease [abstract no: TH‐PO581]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00615825] JardineAG , FellstromB , ColeE , LoganJ , HoldaasH . New targets for cardiovascular risk reduction in renal transplant recipients: post‐hoc analyses of the ALERT study [abstract no: SU‐PO991]. Journal of the American Society of Nephrology2004;15(Oct):746A. [CENTRAL: CN‐00550611] JardineAG , FellstromB , LoganJO , ColeE , NybergG , Gronhagen‐RiskaC , et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases2005;46(3):529‐36. [MEDLINE: 16129216] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post‐hoc subgroup analyses of the ALERT Study. American Journal of Transplantation2004;4(6):988‐95. [MEDLINE: 15147434] JardineAG , HoldaasH , FellstromB , ColeE , NybergG , Gronhagen‐RiskaC , et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU‐FC294]. Journal of the American Society of Nephrology2003;14:64A. [CENTRAL: CN‐00724902] JardineAG , HoldaasH , FellstromB , the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation2004;4(Suppl 8):488. [CENTRAL: CN‐00509253] NorbyG , SoveriI , FellstromB , JardineA , ColeE , MaerzW , et al. C‐Reactive protein (CRP) and interleukin‐6 (IL‐6) are associated with long‐term renal and cardiac outcomes in renal transplant recipients [abstract no: SA‐PO446]. Journal of the American Society of Nephrology2007;18(Abstracts):438A‐9A. [CENTRAL: CN‐00716046] NorbyGE , HolmeI , FellstromB , JardineA , ColeE , AbediniS , et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo‐controlled study. Arthritis &amp; Rheumatism2009;60(4):1060‐4. [MEDLINE: 19333947] OienCM , ReisaeterAV , OsI , JardineA , FellstromB , HoldaasH . Gender‐associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation2006;20(3):374‐82. [MEDLINE: 16824157] SingerJB , HoldaasH , JardineAG , FellstromB , OsI , BermannG , et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research2007;48(9):2072‐8. [MEDLINE: 17563401] SoveriI , AbediniS , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation2009;23(6):914‐20. [MEDLINE: 19594771] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation2008;86(2S):212. [CENTRAL: CN‐00757239] SoveriI , HoldaasH , JardineA , ErikssonN , FellstromB . Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation2008;86(2S):43. [CENTRAL: CN‐00757241] ">ALERT 2001</a> population had experienced a previous myocardial infarction; additional studies in this population would provide new data for this specific population. </p> </section> <section id="CD005019-sec-0082"> <h3 class="title" id="CD005019-sec-0082">Quality of the evidence</h3> <p>Overall, outcome data were obtained from a single study at lower risk of bias. However, the vast majority of studies evaluated failed to specify whether randomisation allocation was concealed, outcome assessors were blinded or data were analysed on an intention‐to‐treat basis. </p> </section> <section id="CD005019-sec-0083"> <h3 class="title" id="CD005019-sec-0083">Potential biases in the review process</h3> <p>While the review process was strengthened by being undertaken by two or more independent authors; a comprehensive search of the literature designed by a specialist librarian that included the grey literature; and the examination of all potentially relevant outcomes; potential biases exist in the review process. </p> <p>The main weakness of this review was the relative paucity of studies available in people with a kidney transplant. The data nearly completely relies on a single large study and suggest the potential for benefit for statins on cardiovascular and mortality outcomes, but more research is needed. Reliance on a single study also reduces the generalizability of the findings to populations that have not been studied, particularly people with a functioning kidney transplant who have experienced an acute cardiovascular event. Moreover, evidence of study heterogeneity was found in some analyses, including total cholesterol, LDL cholesterol and triglycerides that could not be fully explained by prespecified subgroup analyses. Since meta‐analysis assumes that a mean value estimating the effects of an intervention can be determined by combining similar studies, unexplained heterogeneity within a meta‐analysis reduces the reliability of the available evidence, although it should be noted that serum total cholesterol is a surrogate outcome. </p> </section> <section id="CD005019-sec-0084"> <h3 class="title" id="CD005019-sec-0084">Agreements and disagreements with other studies or reviews</h3> <p>In this review update, we have confirmed the findings of our earlier version of this review (<a href="./references#CD005019-bbs2-0103" title="NavaneethanSD , PerkovicV , JohnsonDW , NigwekarSU , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD005019.pub3] ">Navaneethan 2009c</a>) that while point estimates of treatment effect indicate statins reduce cardiovascular death and major cardiovascular events, insufficient evidence results in uncertain treatment effects that include the possibility of no benefit for people with a functioning kidney transplant. Additional evidence is particularly needed to provide high quality data for treatment‐related harm. Statins have been clearly shown to reduce coronary‐related mortality by approximately 20% in people with or at risk of cardiovascular disease (<a href="./references#CD005019-bbs2-0063" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267‐78. [MEDLINE: 16214597] ">Baigent 2005</a>) in broader non‐renal populations, and reduce mortality and major cardiovascular events by one‐fifth in people with earlier stages of CKD who are not on dialysis (<a href="./references#CD005019-bbs2-0092" title="NavaneethanSD , PansiniF , PerkovicV , MannoC , PellegriniF , JohnsonDW , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007784] ">Navaneethan 2009a</a>). Taking into account baseline risk of disease, treating 1000 people with cardiovascular disease or similarly treating 1000 people with CKD not on dialysis might be expected to prevent 25 to 50 deaths over five years. The results of this current review are remarkably similar to findings in the general population, suggesting that major cardiovascular events are reduced in relative terms by 16% in studies in which LDL cholesterol was lowered on average by 1.1 mmol/L, although further evidence is needed to improve our confidence in this result. Intense lipid‐lowering has been associated with additional cardiovascular benefits in broader non‐renal populations (<a href="./references#CD005019-bbs2-0068" title="Cholesterol Treatment Trialists’ (CTT) Collaboration, BaigentC , BlackwellL , EmbersonJ , HollandLE , ReithC , et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170,000 participants in 26 randomised trials. Lancet2010;376(9753):1670‐1681. ">CTT Collaboration 2010</a>); a study evaluating the benefits and (particularly) harms of higher dose statins in people with a kidney transplant is now appropriate. </p> <p>Apart from the cholesterol lowering effects, statins are known to have anti‐inflammatory, anti‐proliferative and immunosuppressive effects (<a href="./references#CD005019-bbs2-0066" title="CorsiniA , MazzottiM , RaiteriM , SomaMR , GabbianiG , FumagalliR , et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG‐CoA reductase. Atherosclerosis1993;10(1):117‐25. [MEDLINE: 8216498] ">Corsini 1993</a>; <a href="./references#CD005019-bbs2-0085" title="KurakataS , KadaM , ShimadaY , KomaiT , NomotoK . Effects of different inhibitors of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology1996;34(1):51‐61. [MEDLINE: 8880225] ">Kurakata 1996</a>). These pleiotropic effects noted by in‐vitro studies suggested their possible impact on acute allograft rejection (<a href="./references#CD005019-bbs2-0088" title="MassyZA , KeaneWF , KasiskeBL . Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet1996;347(8994):102‐3. [MEDLINE: 8538301] ">Massy 1996</a>). Earlier, observational studies have indicated a possible role for statins in decreasing allograft rejection and two studies have shown that statins significantly reduced acute allograft rejection rates (<a href="./references#CD005019-bbs2-0008" title="KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ . Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]. Transplantation2000;69(8 Suppl):S225. [CENTRAL: CN‐00446023] KasiskeBL , Heim‐DuthoyKL , SingerGG , WatschingerB , GermainMJ , BastaniB . The effects of lipid‐lowering agents on acute renal allograft rejection. Transplantation2001;72(2):223‐7. [MEDLINE: 11477342] ">Kasiske 2001</a>; <a href="./references#CD005019-bbs2-0020" title="TuncerM , SuleymanlarG , ErsoyFF , YakupogluG . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings2000;32(3):622‐5. [MEDLINE: 10812143] ">Tuncer 2000</a>) but other studies have not confirmed this finding (<a href="./references#CD005019-bbs2-0019" title="AsbergA , HoldaasH , JardineAG , EdvardsenC , HartmannA . Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation2003;17(4):385‐90. [MEDLINE: 12868997] HoldaasH , JardineA , HolmeI , SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation1999;14(9):A319. [CENTRAL: CN‐00484378] HoldaasH , JardineA , WheelerD . Fluvastatin (lescol) demonstrates significant lipid‐lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul (Turkey). 2001. [CN‐00445759] HoldaasH , JardineAG , WheelerDC , BrekkeIB , ConlonPJ , FellstromB , et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International2001;60(5):1990‐7. [MEDLINE: 11703619] ">SOLAR Study 2001</a>; <a href="./references#CD005019-bbs2-0014" title="RendersL , Mayer‐KadnerI , KochC . Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients. Nephrology Dialysis Transplantation2001;16(1):141‐6. [MEDLINE: 11209008] RendersL , Mayer‐KadnerI , KochC , BurkhardtK , VeelkenR , SchmiederR , et al. Cerivastatin and atorvastatin: efficacy, safety and drug‐interaction of the new HMG‐COA reductase inhibitors in renal transplant patients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):694A. [CENTRAL: CN‐00447381] ">Renders 2001</a>; <a href="./references#CD005019-bbs2-0015" title="SahuK , SharmaR , GuptaA . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation2001;15(3):173‐5. [MEDLINE: 11389707] SharmaRK , SahuKM , GuptaA , GulatiS , AgarwalDK , KumarA , et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation1999;14(9):A288. [CENTRAL: CN‐00485837] ">Sahu 2001</a>). A meta‐analysis of the role of statins in heart transplant recipients has concluded that statins decrease allograft rejection episodes and improve one year heart transplant survival (<a href="./references#CD005019-bbs2-0091" title="MehraMR , RavalNY . Metaanalysis of statins and survival in de novo cardiac transplantation. Transplantation Proceedings2004;36(5):1539‐41. [MEDLINE: 15251380] ">Mehra 2004</a>), findings which at present cannot be confirmed by this review of studies conducted in kidney transplant recipients. </p> <p>The NKF‐DOQI guidelines recommend initiating low dose statins in kidney transplant recipients when LDL cholesterol is above 100 mg/dL in addition to therapeutic lifestyle changes (<a href="#CD005019-tbl-0002">Table 1</a>) (<a href="./references#CD005019-bbs2-0083" title="KasiskeB , CosioFG , BetoJ , BoltonK , ChaversBM , GrimmRJr , et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation2004;4(Suppl 7):13‐53. [MEDLINE: 15027968] ">Kasiske 2004</a>). The European Best Practice guidelines currently recommend initiating statins when LDL cholesterol is above 130 mg/dL (<a href="./references#CD005019-bbs2-0070" title="EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long‐term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrology Dialysis Transplantation2002;17(Suppl 4):26‐8. [MEDLINE: 12091631] ">EBPG 2002</a>). Recently released Kidney Disease Improving Global Outcomes guidelines also recommend lowering LDL cholesterol levels to below 100 mg/dL and endorse the NKF‐DOQI guidelines recommendations (<a href="./references#CD005019-bbs2-0084" title="Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant2009;9:S1‐155. ">KDIGO 2009</a>). Our analysis has shown the use of statins decrease LDL by an average of 45 mg/dL (1.1 mmol/L) and their use may be supported by these surrogate outcomes. We were not able to evaluate whether treatment effects of statins on cardiovascular and mortality outcomes were dependent on cholesterol lowering; recent data in the general population showing benefits for statins even in people with LDL cholesterol levels below 130 mg/dL (3.4 mmol/L, <a href="./references#CD005019-bbs2-0081" title="RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. ">JUPITER 2008</a>) suggest cholesterol targets in people who have a kidney transplant may not be necessary. A similar study evaluating effects of statins in kidney transplant recipients irrespective of serum cholesterol levels may be warranted. </p> <div class="table" id="CD005019-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Published guidelines on hyperlipidaemia management with statins in kidney transplant patients</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Guidelines</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Lipid parameters</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney Disease Improving Global Outcomes (<a href="./references#CD005019-bbs2-0084" title="Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant2009;9:S1‐155. ">KDIGO 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDL ≥100 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TLC + statin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Kidney Foundation Disease Outcomes Quality initiative (NKF‐DOQI) (<a href="./references#CD005019-bbs2-0093" title="National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. American Journal of Kidney Diseases2002;39(2):S1‐S266. [MEDLINE: 11904577] ">NKF 2002</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD005019-list-0009"> <li> <p>LDL 100‐129 mg/dL</p> </li> <li> <p>LDL &gt; 130 mg/dL</p> </li> <li> <p>TG &gt; 200 mg/dL and non‐HDL &gt; 130 mg/dL</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD005019-list-0010"> <li> <p>TLC + low dose statin</p> </li> <li> <p>TLC + maximum dose statin</p> </li> <li> <p>TLC + maximum dose statin</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>European Best Practice Guidelines (<a href="./references#CD005019-bbs2-0070" title="EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long‐term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrology Dialysis Transplantation2002;17(Suppl 4):26‐8. [MEDLINE: 12091631] ">EBPG 2002</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LDL &gt; 130 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TLC + low dose statin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canadian Society of Nephrology (CSN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>British Renal Association (BRA)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caring for Australians with Renal Impairment (CARI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LDL‐ low‐density lipoprotein cholesterol; Non‐HDL ‐ Non high‐density lipoprotein cholesterol; TC ‐ total cholesterol; TG ‐ triglycerides; TLC ‐ therapeutic lifestyle changes </p> </div> </div> <p>A previously published systematic review, which looked at the impact of statins in kidney transplant recipients, concluded that statins reduced lipid parameters significantly without any reduction in allograft rejection rates (<a href="./references#CD005019-bbs2-0086" title="LentineKL , BrennanDC . Statin use after renal transplantation: a systematic quality review of trial‐based evidence. Nephrology Dialysis Transplantation2004;19(9):2378‐86. [MEDLINE: 15252155] ">Lentine 2004</a>); our review confirms these findings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005019-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005019-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005019-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005019-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 1 Cardiovascular mortality." data-id="CD005019-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 1 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 2 All‐cause mortality." data-id="CD005019-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 2 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 3 Major cardiovascular events." data-id="CD005019-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 3 Major cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 4 Fatal and non‐fatal myocardial infarction." data-id="CD005019-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 4 Fatal and non‐fatal myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 5 Fatal and non‐fatal stroke." data-id="CD005019-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 5 Fatal and non‐fatal stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 6 Elevated creatine kinase." data-id="CD005019-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 6 Elevated creatine kinase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 7 Elevated liver enzymes." data-id="CD005019-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 7 Elevated liver enzymes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 8 Withdrawal due to adverse events." data-id="CD005019-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 8 Withdrawal due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 9 Cancer." data-id="CD005019-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 9 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 10 Total cholesterol." data-id="CD005019-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 10 Total cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 11 LDL cholesterol." data-id="CD005019-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 11 LDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 12 HDL cholesterol." data-id="CD005019-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 12 HDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 13 Triglycerides." data-id="CD005019-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 13 Triglycerides.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 14 End‐stage kidney disease." data-id="CD005019-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 14 End‐stage kidney disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 15 Acute allograft rejection." data-id="CD005019-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 15 Acute allograft rejection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 16 Proteinuria." data-id="CD005019-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 16 Proteinuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005019-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/urn:x-wiley:14651858:media:CD005019:CD005019-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_t/tCD005019-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statins versus placebo, Outcome 17 Glomerular filtration rate." data-id="CD005019-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Statins versus placebo, Outcome 17 Glomerular filtration rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/media/CDSR/CD005019/image_n/nCD005019-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005019-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Statin versus placebo or no treatment for adults kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population: adults with chronic kidney disease</b> </p> <p><b>Settings: kidney transplant recipients</b> </p> <p><b>Intervention: statin</b> </p> <p><b>Comparison: placebo or no treatment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Statin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> (13 to 21) </p> <p><b>3 fewer</b> (7 fewer to 1 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> </p> <p>(0.66 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2102 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> (12 to 37) </p> <p><b>2 more</b> (8 fewer to 17 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> </p> <p>(0.63 to 1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2760 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (2 to 5) </p> <p><b>2 fewer</b> (3 fewer to 0 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> </p> <p>(0.45 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2322 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Absolute approximate event rates of outcomes/year were derived from previously published observational cohort studies. Absolute numbers of people with a functioning kidney transplant with cardiovascular or mortality events avoided or incurred per 1000 treated were estimated using these assumed risks together with the estimated relative risks (and 95% confidence intervals) (<a href="./references#CD005019-bbs2-0062" title="Australia , New ZealandDialysis , Transplant Registry(ANZDATA) . The 33rd Annual Report 2010. http://www.anzdata.org.au/v1/report_2010.html (accessed 19 December 2013). ">ANZDATA 2010</a>; <a href="./references#CD005019-bbs2-0087" title="LentineKL , BrennanDC , SchnitzlerMA . Incidence and predictors of myocardial infarction after kidney transplantation. Journal of the American Society of Nephrology : JASN2005;16(2):496‐506. [PUBMED: 15615820] ">Lentine 2005</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005019-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Published guidelines on hyperlipidaemia management with statins in kidney transplant patients</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Guidelines</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Lipid parameters</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney Disease Improving Global Outcomes (<a href="./references#CD005019-bbs2-0084" title="Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant2009;9:S1‐155. ">KDIGO 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDL ≥100 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TLC + statin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Kidney Foundation Disease Outcomes Quality initiative (NKF‐DOQI) (<a href="./references#CD005019-bbs2-0093" title="National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. American Journal of Kidney Diseases2002;39(2):S1‐S266. [MEDLINE: 11904577] ">NKF 2002</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD005019-list-0009"> <li> <p>LDL 100‐129 mg/dL</p> </li> <li> <p>LDL &gt; 130 mg/dL</p> </li> <li> <p>TG &gt; 200 mg/dL and non‐HDL &gt; 130 mg/dL</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD005019-list-0010"> <li> <p>TLC + low dose statin</p> </li> <li> <p>TLC + maximum dose statin</p> </li> <li> <p>TLC + maximum dose statin</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>European Best Practice Guidelines (<a href="./references#CD005019-bbs2-0070" title="EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long‐term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrology Dialysis Transplantation2002;17(Suppl 4):26‐8. [MEDLINE: 12091631] ">EBPG 2002</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LDL &gt; 130 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TLC + low dose statin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canadian Society of Nephrology (CSN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>British Renal Association (BRA)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caring for Australians with Renal Impairment (CARI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No guideline available</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>LDL‐ low‐density lipoprotein cholesterol; Non‐HDL ‐ Non high‐density lipoprotein cholesterol; TC ‐ total cholesterol; TG ‐ triglycerides; TLC ‐ therapeutic lifestyle changes </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Published guidelines on hyperlipidaemia management with statins in kidney transplant patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/full#CD005019-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005019-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statins versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.45, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.63, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatal and non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatal and non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Elevated creatine kinase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.39, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Elevated liver enzymes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.33, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐42.43 [‐51.22, ‐33.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.19 [‐52.59, ‐33.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.69 [‐10.35, ‐1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.28 [‐34.29, ‐20.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 End‐stage kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.94, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Acute allograft rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.17, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Glomerular filtration rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statins versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005019.pub4/references#CD005019-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005019.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005019-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005019-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005019-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD005019-note-0001">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD005019-note-0002">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005019\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005019\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005019\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005019\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005019.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005019.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005019.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005019.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005019.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715469429"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005019.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715469433"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005019.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d87dc7b099374',t:'MTc0MDcxNTQ2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 